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ABSTRACT OF THE DISSERTATION 
THE IMMUNOSUPPRESSIVE ROLE OF EDN3/EDNRB SIGNALING IN THE 
MELANOMA MICROENVIRONMENT 
by 
Juliano Freitas 
Florida International University, 2019 
Miami, Florida 
Professor Lidia Kos, Major Professor 
Endothelins are cytokines ubiquitously expressed in the microenvironment of 
several tumors. In melanoma is not clear whether stromal cells respond to the 
endothelin present in the microenvironment. To address this question, I generated 
tumors derived from different murine melanoma cell lines (B16F10, YUMM1.7, 
YUMMER1.7) in a transgenic mouse that overexpresses endothelin 3 (Edn3) by 
keratinocytes in the skin (K5-Edn3). Tumors from all the cell lines grew larger and 
were more aggressive when Edn3 was overexpressed in the skin. In tumors 
derived from YUMM1.7-GFP cells, very few tumorigenic cells expressed the Edn3 
receptor, Endothelin receptor b (Ednrb) suggesting an environmental role for 
endothelin signaling in melanoma microenvironment. The present study showed 
for the first time that Ednrb is expressed in several cell populations inside 
melanoma microenvironment. The clinical relevance of the finding was validated 
using publicly available RNA-seq data from melanoma patients. Regulatory T cells 
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(Tregs) was the only population that was numerically different when K5-Edn3 
tumors were compared to wild-type tumors suggesting that Edn3 promotes Treg 
enrichment in melanoma microenvironment.  
The present study supports the notion that endothelin promotes the formation 
of an immunosuppressive milieu in melanoma facilitating escape from tumor 
immunity. Endothelin was required for immune escape of highly immunogenic 
melanoma cells YUMMER1.7. The immunosuppressive features of Tregs were 
enhanced in presence of Edn3. The master regulator of Tregs’ suppressive 
functions, FOXP3, was remarkably upregulated in K5-Edn3 tumors as well as 
immunosuppressive cytokines TGF-β and IL-10. Overexpression of Edn3 in the 
tumor microenvironment prevented the expansion of CTLs possibly via GZB-
mediated cytolysis. Expression of chemokines and inflammatory cytokines were 
downregulated in K5-Edn3 tumors. Cytokines that elicit anti-tumor immunity, 
exhibited reduced levels in K5-Edn3 tumors. The YUMM1.7-GFP tumors exposed 
to high levels of Edn3 were sensitive to immune checkpoint inhibitor (anti-CTLA-4) 
as well as to Ednrb blockage (BQ-788). The response to BQ-788 was more 
pronounced suggesting that EDNRB targeting might be an alternative therapeutic 
strategy for melanoma patients that are under immunotherapy regimen.  
In conclusion, the present study indicates that Edn3/Ednrb signaling has an 
important role in the melanoma microenvironment where it mediates 
immunosuppression resulting in escape from tumor immunity. 
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1.1. Melanoma 
Melanoma is a highly metastatic cancer and the number of new cases of 
melanoma in the United States has been increasing for the last 30 years. 
According to the American Cancer Society 96,480 new cases will be diagnosed 
and about 7,230 people will die from melanoma in 2019. Melanoma has an overall 
mortality rate of approximately 20% and is responsible for 80% of all deaths related 
to cutaneous tumors. The high mortality rate associated with melanoma is a result 
of its remarkable metastatic potential (Paluncic et al., 2016). 
 Melanoma Biology 
Melanoma results from the transformation of pigment cells, namely 
melanocytes. Melanocytes are neural crest-derived cells that during development 
migrate to the skin where they reside in the basal layer of the epidermis and hair 
follicles (Colombo et al., 2011). Melanocytes represent a small population within 
the skin where there are 10 keratinocytes to each melanocyte (Kanitakis, 2002). 
Melanocytes are specialized in the production of melanin, the main natural pigment 
in the skin, which affords a protective effect to keratinocytes against ultraviolet 
(UV)-induced DNA damage (Costin and Hearing, 2007). Under UV exposure 
keratinocytes produce α-Melanocyte stimulating hormone (αMSH), which binds to 
the melanocortin 1 receptor (MC1R) receptor in melanocytes triggering the 
production of melanin that is eventually delivered to keratinocytes (Schauer et al., 
1994; Chakraborty et al., 1996). Melanocytes can produce two different types of 
melanin: eumelanin, a dark-brown pigment that protects against UV damage and 
pheomelanin, a yellow-red pigment that is less protective. Individuals with red hair 
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and fair skin phenotype harbor MC1R variants and therefore are more susceptible 
to the deleterious effects of UV radiation (Lo and Fisher, 2014). 
The major risk factor for melanoma is sun exposure which is represented by 
the astounding number of UV-signature mutations, such as C>T and G>T, present 
in melanoma tumors (Lawrence et al., 2013). In fact, melanoma has a median 
number of >10 mutation/megabase of DNA, which makes it the top tumor type with 
respect to frequency of somatic mutations (Alexandrov et al., 2013; TCGA, 2015). 
Very intriguing is the observation that many UV-associated alterations are 
passenger mutations and have no biological effect as opposed to driver mutations 
which are oncogenic (Hawryluk and Tsao, 2014). Common mutations found in 
melanoma, namely BRAFV600E, NRASQ61L, KITV559A, and GNA11Q209L, lack the 
typical UV-signatures (Hodis et al., 2012). Nevertheless, the fact that common 
mutations found in melanoma lack UV-signature does not mean sunlight is not 
implicated in the mutation load characteristic of melanoma (Schadendorf, Fisher, 
et al., 2015). Secondary mutations can be generated by the interaction of melanin 
with UV light and indirectly modify the DNA (Noonan et al., 2012). It should be 
noted though that genetic alterations in tumor suppressor genes like tumor protein 
53 (TP53), phosphatase and tensin homolog (PTEN), and cyclin dependent kinase 
inhibitor 2A (CDKN2A) have a high number of UV-induced mutations (Hodis et al., 
2012). 
Depending on the amount of cumulative UV-exposure melanomas can be 
classified as non-chronically sun damaged (non-CSD) or chronically sun damaged 
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(CSD). Non-CSD melanomas are more prevalent in young patients and arise in 
regions of the body with intermittent sun exposure. Non-CSD melanomas harbor 
the BRAFV600E mutation and a modest level of mutation burden. Older patients that 
have been continually exposed to UV radiation tend to develop CSD melanomas, 
which possess an enormous mutation load and carry different genetic alterations, 
namely BRAFnonV600E, NRAS and neurofibromatosis type 1 (NF1) mutations (Shain 
and Bastian, 2016). 
 Genetic alterations during melanoma development 
Melanoma development has long been depicted as a linear progression (Figure 
1.1) starting from benign lesions such as melanocytic and dysplastic naevi that 
transform into melanoma in situ which eventually evolves to more malignant 
lesions like invasive and metastatic melanoma (Shain and Bastian, 2016). A 
melanocytic naevus is characterized by limited proliferation of melanocytes 
through the constitutive activation of mitogen-activated protein kinase (MAPK) 
signaling pathway initiated by BRAFV600E mutation (Shain et al., 2015). Neavi 
formation resulting from Braf activation has been elegantly demonstrated by a 
mouse model in which only melanocytes harbor the BrafV600E mutation. These 
mutant mice developed lesions very similar to melanocytic naevi found in humans 
(Dankort et al., 2009). It is widely accepted that melanocytic naevus is the benign 
precursor of non-CSD melanoma because of the fact that both types of lesions 
share high amounts of BRAFV600E mutations (Pollock et al., 2003). On the other 
hand, CSD melanomas, which have BRAFnonV600E mutations and tend to arise from 
de novo lesions, have no evolutionary connections with melanocytic naevi (Shitara 
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et al., 2014). In the absence of additional genetic alterations melanocytic naevi are 
directed to a senescence-like stage defined by cell cycle arrest and abrogation of 
cell proliferation. The BRAFV600E mutation is an important trigger of the senescence 
observed in melanocytic naevi illustrating the well-known oncogene-induced 
senescence phenomenon (Damsky and Bosenberg, 2017). The immune system 
may also enhance senescence as activation of BRAF stimulates the secretion of 
pro-inflammatory mediators interleukin 6 (IL-6) and interleukin-8 (IL-8) (Kuilman et 
al., 2008). Interestingly, the expression of these inflammatory mediators are 
augmented in melanocytic naevi when compared to more aggressive lesions 
(Ahmed et al., 1995).  
The vast majority of melanocytic naevi remain dormant and never give rise to 
melanoma. It is estimated that during a man’s lifetime there is a risk of 1/3,000 that 
a nevus will progress to melanoma and for women the odds are even lower 
(1/11,000) (Tsao et al., 2003). Melanocytic naevi rarely acquire mutations in the 
telomerase reverse transcriptase (TERT) promoter and heterozygous alteration in 
the CDNK2A locus, which activate telomerase and disturb the cell cycle 
checkpoints, respectively (Shain et al., 2015). These alterations result in the 
formation of an intermediate lesion between benign and malignant melanoma 
called dysplastic naevus (Elder et al., 1980). Mutations in the TERT promoter are 
considered one of the earliest secondary mutations present in the naevus and 
roughly 80% of dysplastic naevi exhibit these alterations (Shain et al., 2015). 
Individuals with germline variants of CDNK2A tend to develop numerous de novo 
dysplastic naevi leading to dysplastic nevus syndrome (Shain and Bastian, 2016), 
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and have 70% of chance to develop familial melanomas during their lifetime (De 
Snoo and Hayward, 2005). Some dysplastic naevi developed sporadically have 
greater number of NRAS mutation compared to the amount of BRAFV600E mutation 
present in the melanocytic naevi suggesting that in some case melanocytic and 
dysplastic naevi do not follow the same evolutionary pathway (Shain et al., 2015). 
Immune surveillance seems to be tightly associated with emergence and growth 
of naevi. In a condition termed eruptive naevi individuals abruptly develop 
numerous naevi harboring the BRAFV600E mutation and the phenomenon is 
particularly common in immunosuppressed patients (Sekulic et al., 2010). 
Transformed melanocytes with excessive proliferation restricted to the 
epidermis is a characteristic of melanoma in situ. In addition to the heterozygous 
mutations in CDKN2A and alterations in the TERT promoter in situ melanomas 
have increased mutations affecting downstream effectors of MAPK signaling 
pathway (Shain and Bastian, 2016). Approximately 50% of in situ melanomas have 
the BRAFV600E mutation, and 30% harbor the NRASQ161L mutation. (Omholt et al., 
2002, 2003; TCGA, 2015). Interestingly, those mutations are mutually exclusive 
implying an absence of selective advantage in harboring many alterations in the 
MAPK signaling pathway (Damsky and Bosenberg, 2017). Inactivation of tumor 
suppressor gene NF1, a negative regulator of RAS, is the third most common 
genetic alteration in melanomas and is most prevalent in older patients 
(Krauthammer et al., 2015; TCGA, 2015). There is a fourth subtype of melanoma 
that does not harbor either of those three classical mutations (BRAF, NRAS or 
NF1) in the MAPK  signaling pathway and therefore is considered triple wild-type 
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melanoma. Mutations in the receptor tyrosine kinase KIT and in the α subunits of 
G-protein GNA11 and GNAQ are more frequent in triple wild-type melanomas 
(TCGA, 2015). In situ melanoma may endure for decades gathering a variety of 
mutations before acquiring the ability of breaking the epidermis and invading the 
surrounding tissues (Shain and Bastian, 2016).  
Once melanoma is able to occupy the dermis it is considered to be at the 
invasive stage. The level of invasiveness is associated with reduced survival and 
used as a prognostic factor (Schadendorf, Fisher, et al., 2015). A crucial genetic 
alteration found in early invasive melanomas is the inactivation of the second copy 
of CDKN2A (Shain et al., 2015). Alternative splicing of CDKN2A locus produces 
two different proteins, p16INK4A, and p14ARF (or p19ARF in mice), that are considered 
major tumor suppressors in melanoma (Damsky and Bosenberg, 2017). The 
protein p16INK4A phosphorylates Rb preventing cell cycle progression in G1/S 
phase (LaPak and Burd, 2014) while p14ARF inhibits p53 degradation by MDM2 
(Maggi et al., 2014). A mouse model with the BrafV600E mutation in combination 
with Cdkn2a inactivation develops melanomas with 100% of penetrance as mice 
age (Damsky et al., 2015) and transgenic mice harboring the NrasQ61K mutation 
and homozygous deletion of Ink4a gene develop invasive melanomas in six 
months (Ackermann et al., 2005).  
Later in the progression of the primary tumor the phosphatase PTEN is often 
lost as metastatic melanomas have high frequency of PTEN inactivation 
(Reifenberger et al., 2000). Silencing of PTEN associated with the BRAFV600E 
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mutation is observed in 80% of melanoma cell lines (Tsao et al., 2004) and 40% 
of melanoma patients (Hodis et al., 2012). Transgenic mice have confirmed that 
BrafV600E mutation alone is not sufficient to produce invasive melanoma, but when 
it is associated with the Pten deletion, mice develop melanomas with high 
penetrance that metastasize to lymph nodes and lungs (Dankort et al., 2009). The 
protein p53 is another tumor suppressor altered during late stages of melanoma 
(Shain and Bastian, 2016). Disruption of p53 in melanoma is lower compared to 
other types of solid tumors but mutations in the TP53 gene are more frequent in 
metastatic lesions when compared to primary melanomas (Stretch et al., 1991).  
 Melanoma Metastasis 
Melanoma is referred as metastatic after tumorigenic cells leave the primary 
tumors and disseminate to distant sites in the body. Once melanoma becomes 
metastatic, the patients has a very poor prognosis with the 1-year overall survival 
rate around 25% and the median survival of 6.2 months (Korn et al., 2008). 
Melanoma generally establishes secondary lesions in brain, lymph nodes, skin and 
lung (Murakami, Cardones and Hwang, 2004), the latter being the most common 
tissue affected in approximately 40% patients with metastatic disease (Balch et al., 
1983). The nearest draining lymph to primary tumors is generally thought to be the 
first site of dissemination of metastatic cells and the colonization of visceral organs 
happens afterwards (Shain and Bastian, 2016). The presence of melanoma cells 
in the sentinel lymph node has long been accepted as prognostic factor for patients 
(Balch et al., 2009). Yet, the complete resection of the sentinel lymph node does 
not seem to improve patient survival (Kingham et al., 2010).  
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Recently it has been suggested that metastasis might be formed earlier in the 
history of the primary tumor and the idea challenges the classical paradigm of 
linear progression of melanoma metastasis formation (Gassenmaier et al., 2017). 
Currently, there are some indications that metastasis formation takes place in 
parallel to the development of the primary tumor (Damsky, Theodosakis and 
Bosenberg, 2014; Sanborn et al., 2015), although the molecular mechanisms 
underlying the parallel progression model are not established yet (Figure 1.1). 
Patients with no signs of metastatic disease have melanoma cells (Reid et al., 
2013) and even benign melanocytes detected in their bloodstream (Hall et al., 
2012). In the condition termed nodal naevi, melanocytes carrying BRAFV600E 
mutation are found in lymph nodes (Taube et al., 2009) and nodal naevi have been 
detected in patients with no melanoma disease (Bautista, Cohen and Anders, 
1994). Further observation supporting the parallel progression model of melanoma 
metastasis includes the fact that 5% of patients with metastatic disease have no 
detectable primary tumor (Giuliano, Moseley and Morton, 1980). It is reasonable 
to speculate that metastatic features are established during benign stages of 
melanoma development rather than acquired during progression, but the 
development of fully metastatic phenotype would require further mutations gained 
later during tumorigenesis (Shain and Bastian, 2016).  The linear and parallel 
models of melanoma dissemination are not necessarily mutually exclusive since 
both pathways are likely to generate relevant metastatic disease (Damsky, 
Theodosakis and Bosenberg, 2014).  
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1.2. Tumor Microenvironment 
Cancers had long been viewed as an assembly of heterogeneous transformed 
cells. The reductionist view of tumors has changed over the past decades to a 
more complex landscape. Presently, a tumor is seen as an “organ” where an 
elaborate and bidirectional interaction between cancer cells and non-malignant 
cells from the surrounding stromal tissue takes place (Hanahan and Weinberg, 
2011). Inside these “organs” there is a complex network called the tumor 
microenvironment (TME) that includes not only the cancer cells, but also the 
tumor stroma which is a milieu that comprises non-neoplastic cells, extracellular 
matrix (ECM), and the signaling molecules they are embedded in (Spano and 
Zollo, 2012). The cellular component of the TME is diverse and include fibroblasts, 
endothelial cells, and a variety of immune cell populations namely, macrophages, 
neutrophils, myeloid derived suppressor cells (MDSC), dendritic cells (DC), natural 
killer (NK) cells, and T and B lymphocytes subtypes (Quail and Joyce, 2013). 
The TME is a not an inert component but rather, a continuously evolving system 
modulated by oncogenic and environmental signals and, in response to the 
metamorphic TME, tumor cells are also modified and become more aggressive 
(Binnewies et al., 2018). Thus, it is now well established that the TME plays a 
crucial role during tumor development, supporting tumor growth, invasion and 
metastasis (Spano and Zollo, 2012). In some cancers the malignant cells represent 
only 30% of all cell types existing in the TME (Becker et al., 2013). Furthermore, 
the amount of different cell populations in the tumor stroma varies drastically when 
different tumors are compared or even among patients harboring the same type of 
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cancer. Indeed, each tumor has its own “TME fingerprint” that can be addressed 
for prognostic and therapeutic purposes (Liu, Workman and Vignali, 2016).   
Tumor formation and development is associated with a deregulated 
microenvironment as observed by the increased incidence of cancers in individuals 
that experience chronic inflammation or immunosuppression (Palucka and 
Coussens, 2016). Patients with long-term colitis have seven times more chance to 
develop colon cancer than those with no inflammation in their colon (Beaugerie et 
al., 2013). Lung and skin cancer arise more frequently in organ transplant 
recipients that are under immunosuppressive regimen (Stewart et al., 1995). Upon 
the initial transformation of cells in a tissue, the tumorigenic cells recruit cancer-
associated fibroblasts (CAFs). Cancer-associated fibroblasts establish a crosstalk 
with the tumorigenic cells based on chemokines and growth factors, which in turn 
attract immune cells to participate in the network. Immune cells play ambiguous 
roles during tumorigenesis, either antagonizing or supporting tumors and the 
balance between tumor suppressing or promoting immune cells will determine the 
fate of tumor progression (Spano and Zollo, 2012).  
Emerging tumor cells overexpress mutated or new antigens that are collectively 
called tumor-associated antigens (TAA). Tumor-associated antigens can be 
recognized by DCs and presented to CD4+ Helper T cells, which activate CD8+ 
cytotoxic T cells (CTLs) that will eventually eliminate the cancer cells (Lee, 2017). 
Cancer cells can also reduce their own immune recognition deregulating MHC-I 
expression. However, NK cells can detect the missing self in the tumors and 
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destroy them (Morvan and Lanier, 2016). The elaborate network of immune cells 
devoted to finding and removing cancer cells is termed tumor immunosurveillance 
and is constantly monitoring every host tissue and keeping the body clear of cancer 
cells (Grivennikov, Greten and Karin, 2010; Hanahan and Weinberg, 2011). The 
tumor immunosurveillance hypothesis is supported by the observation that 
immunocompromised mice lacking different populations of lymphocytes are more 
susceptible to induced and spontaneous tumors than their immunocompetent 
counterparts (Shankaran et al., 2001).  
The relationship between cancer and inflammation has long been 
acknowledged. In the mid nineteenth century, it was already demostrated that 
tumors have a high incidence of leukocyte infiltrates (Balkwill and Mantovani, 
2001).  Since immune cells can detect and destroy cancer cells, the presence of 
inflammation in neoplastic contexts had been interpreted as a frustrated attempt 
by the immune system to eliminate the tumor. Some authors described tumors as 
wounds that never heal (Flier, Underhill and Dvorak, 1986). Counterintuitively, over 
the past decades it has become clear that inflammation may endow tumorigenesis. 
The inflammatory milieu is characterized by large amounts of growth, survival and 
angiogenesis factors, which promote tumor growth, evasion of growth suppression 
and angiogenesis, respectively. The large number of reactive oxygen species 
generated during inflammation may also increase the genetic instability through 
mutagenic events in the tumor cells (Condeelis and Pollard, 2006; Hanahan and 
Weinberg, 2011).  
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Inflammation alone is not sufficient for tumor progression because of the 
intense cell recruitment of immune cells to the TME potentially exposes tumor cells 
to immune detection and elimination. Many of the inflammatory mediators are also 
related to the recruitment and activation of immunosuppressive cells such as 
MSDC and regulatory T cells (Tregs) (Umansky and Sevko, 2012). These cells 
show remarkable immunosuppressive and anti-inflammatory activities and are 
able to disturb many mechanisms of immunosurveillance, including but not 
restricted to the impairment of T cell activation, antigen presentation by DC and 
interruption of NK cells cytotoxicity (Quail and Joyce, 2013). Therefore, the 
recruitment of immune cells to the TME is highly advantageous to tumor cells given 
that inflammatory cells foster tumor progression while immunosuppressive cells 
make those anti-tumor recruited cells unable to recognize and kill cancer cells 
(Hanahan and Weinberg, 2011). 
Immunoediting explains the contradictory interaction of immune cells in the 
TME throughout tumor development and progression. The immunoediting concept 
was derived from the findings that immunocompromised mice develop tumors that 
are more immunogenic (more easily detected by the immune cells) than tumors 
arising in immunocompetent mice (Shankaran et al., 2001). According to the 
immunoediting concept, the host immune system prevents tumor formation while 
modulating tumor immunogenicity. Immunoediting happens through a sequence 
of stages starting from elimination, evolving to equilibrium and culminating in the 
escape phase. The elimination phase is when the immunosurveillance system 
detects and eradicates emerging tumors. Rarely, tumors cells that subsist the 
14 
 
forces of immunosurveillance are kept dormant during the equilibrium phase. The  
equilibrium phase is probably the longest phase of  the immunoediting process. 
Throughout equilibrium phase the immune system selects and edits the 
immunogenicity of tumors cells. During the escape phase tumor cells that became 
less immunogenic form visible tumors, further enhanced by the 
immunosuppressive setting installed in TME (Schreiber, Old and Smyth, 2011).  
The TME has recently attracted much attention for its therapeutic opportunities. 
For many years the approach to treat patients with malignant tumors depended 
solely on targeting tumor cells. Tumors initially respond to targeted therapies but 
as a consequence of the genetic instability of malignant cells they become 
resistant to treatments. Presumably, a more effective alternative is to target the 
stromal cells in the TME. Non-transformed cells are genetically stable and offer 
reduced opportunity to circumvent targeted treatments (Quail and Joyce, 2013). 
During the last few years approaches aiming to reprogram the TME and shift the 
balance toward a more anti-tumorigenic phenotype have considerably improved 
patients’ outcome. Many of these strategies, called immunotherapy, are meant to 
boost the host’s immune system to combat cancer. Immunotherapy has produced 
exciting results and in the next decade it is likely that 60% of patients with 
advanced tumors will be treated with immunotherapy (Ledford, 2014).    
 Cell types 
Cells in the TME can be classified as either pro-tumorigenic or anti-tumorigenic. 
Among pro-tumorigenic cells there are macrophages, neutrophils, T and B cells, 
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and MDSCs. The anti-tumorigenic cells are CTLs and NK cells (Hanahan and 
Weinberg, 2011). A more complex classification is defined by the dual role of 
immune cells in the TME: immune cells with an anti-tumorigenic role are “type 1 
cells” whereas those with a pro-tumorigenic role are “type 2 cells”. The CD4+ T 
helper cells TH1, neutrophils N1, and macrophages M1 are all tumor-inhibitory 
cells. In contrast, CD4+ helper cells TH2, neutrophils N2 and macrophages M2 are 
all tumor-promoting cells (Becker et al., 2013). So far, NK cells have not been 
described as playing pro-tumorigenic roles in the TME (Smith and Kang, 2013). 
The “type 1” and “type 2” classification of immune cells in the TME is very useful 
for describing the  basic concepts underlying the TME. However, the classification 
should be viewed with caution because the complexity of TME cannot be reduced 
to an all or none framework (Quail and Joyce, 2013). Another dichotomous 
classification of the TME is focused on its global immunological phenotype. 
Tumors with low number of anti-tumorigenic cells such as CTL, NK and TH1 
lymphocytes, few DCs and high number of immunosuppressive cells (i.e., MSDC 
and Tregs) are considered “cold” tumors. Conversely, “hot” tumors are highly 
inflamed and enriched with effector anti-tumor cells and antigen presenting cells 
(APCs) and therefore are likely to have a better response to immunotherapies 
(Nagarsheth, Wicha and Zou, 2017; Binnewies et al., 2018). A diagrammatic 
representation of the many cell types and their interactions in the TME is shown in 
Figure 1.2. 
.  
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1.2.1.1. Anti-tumorigenic immune cells  
Mature DCs are very efficient APCs that initiate strong anti-tumor response 
upon interaction with lymphocytes (Nagarsheth, Wicha and Zou, 2017). Dendritic 
cells activate lymphocytes when TAAs are presented in presence of co-stimulatory 
signals. The best characterized co-stimulatory signal system is CD28-B7; CD28 is 
expressed by T cells while B7 is expressed in the DC surface. The protein B7 can 
also bind to the inhibitory receptor cytotoxic T lymphocyte associated protein 4 
(CTLA-4), but in binding to CTLA-4 prevents T cell activation (Andersen et al., 
2006). When DCs loaded with TAA encounter naïve CD8+ T cells they promote T 
cell differentiation into TAA-specific CTLs. A similar differentiation process 
happens when DCs find naïve CD4+ T helper cells but in this case T helper cells 
can differentiate into subpopulations with different phenotypes including TH1 and 
TH2 (Palucka and Coussens, 2016). Dendritic cells induce the polarization of CD4+ 
T helper cells towards TH1 or TH2, a process that relies on (interleukin 12) IL-12 
availability. Antigen presentation in presence of IL-12 generates TH1 cells. In 
contrast, when antigens are presented in absence of IL-12, CD4+ T helper cells 
differentiate into TH2 cells (Banchereau and Palucka, 2005).   
The TH1 polarized CD4+ T helper cells are associated with destruction of 
malignant cells. A large number of TH1 cells is correlated with good outcome for 
patients (Galon et al., 2006). The TH1 cells work in coordination with DCs to 
promote the activation of tumor-specific CTLs through cross-presentation of TAAs 
(Dunn, Old and Schreiber, 2004). Another anti-tumor mechanism of TH1 cells is 
via the production of interferon-γ (IFN-γ), which is one of the main modulators of 
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the host response against tumors (Ikeda, Old and Schreiber, 2002). Interferon-γ 
derived from TH1 cells polarizes monocytes towards M1 phenotype (Mantovani et 
al., 2008) and activates the cytotoxic activity of macrophages as well as CTLs 
facing tumors cells (Ikeda, Old and Schreiber, 2002; Becker et al., 2013). 
Cytotoxic T cells (CTLs) is considered the principal cell type of anti-tumor 
immunity (Appay, Douek and Price, 2008) and, not surprisingly, tumors with high 
infiltrates of CTLs are associated with improved prognosis (Clemente et al., 1996; 
Prall et al., 2004; Bachmayr-Heyda et al., 2013). Cytotoxic T cells have two 
strategies to kill cancer cells that require direct cell-cell contact. The first 
mechanism is through the secretion of granules of perforin and granzyme B (GZB) 
in the extracellular space, the other apparatus is via Fas ligand/Fas receptor. Both 
approaches trigger apoptosis in the target cancer cell and must be tightly regulated 
to prevent accidental killing of the CTLs themselves or other neighboring cells. 
Cytotoxic T cells also secret cytokines like IFN-γ and TNF-α that similarly activate 
apoptosis in the target cells (Andersen et al., 2006). Upon long-lasting exposure 
to TAAs, CTLs might enter in a stage called exhaustion, characterized by reduced 
proliferation and cytotoxic activity as well as augmented expression of inhibitory 
receptors such as CTLA-4 and programmed cell death-1 (PD-1). The expression 
of inhibitory receptor ligands by tumor and stromal cells in the TME prevents CTL 
activity. Recently, immunotherapy treatments aiming to block the expression of 
immune checkpoint inhibitors have successfully strengthened tumor infiltrating 
CLTs and provided durable anti-tumor response in patients with advanced tumors 
(Zarour, 2016).  
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Natural killer (NK) cells are cells from the innate immunity system that also have 
strong cytotoxic activity against tumor cells (Corthay, 2014). High tumor incidence 
in animal models (Talmadge et al., 1980) and patients with NK cell deficiencies, 
supports the pivotal role of NK cells in immunosurveillance (Roder et al., 1980). 
Likewise CTLs, NK cells kill tumors cells using granzymes and perforin granules 
as well as death receptor/ligand pathways. The NK cells can discriminate between 
healthy and cancer cells on the basis of the balance between inhibitory and 
activating receptors. Inhibitory receptors detect self-major histocompatibility 
complex-I (MHC-I) in normal cells and prevent the activation of NK cells  (Morvan 
and Lanier, 2016). Cancer cells recurrently downregulate MHC-I expression so 
that they can escape CTL detection. The NK cells detect the missing self on tumors 
cells that escaped CTLs control and this process triggers NK activity. Some cancer 
cells maintain MHC-I expression and express ligands to NK’s activating receptors 
(i.e. NKG2D) and the binding of these ligands also stimulate NK cytotoxic activity 
(Muenst et al., 2016).   
1.2.1.2. Pro-tumorigenic immune cells 
Tumor-associated macrophages (TAMs) are major contributors to tumor cell 
migration, invasion and metastasis. They are mainly localized in the tumor edge 
where they facilitate tumor invasion (Condeelis and Pollard, 2006). Indeed, there 
is a positive correlation between augmented metastatic incidence and high TAM 
infiltration (Hanada et al., 2000). Tumor-associated macrophages mainly show M2 
phenotype in the TME (Rhee, 2016) and are recognized as the main source of 
matrix-degrading proteases which promote tumor cell invasion (Quail and Joyce, 
19 
 
2013). In breast and pancreatic cancer, TAMs are associated with production of 
metalloproteinases (MMP) MMP-2 and MMP-9 (Hagemann et al., 2004) as well as 
cathepsin B and S secretion (Gocheva et al., 2010). Tumor-associated 
macrophages also influence tumor invasion through a signaling loop involving EGF 
and CSF-1. Epidermal growth factor (EGF) secreted by TAMs interacts with its 
receptor on tumor cells and in addition to cell motility, promotes the tumor secretion 
of CSF-1, which in turn stimulates TAMs to produce more EGF (Goswami et al., 
2005). Additionally, TAMs have reduced antigen presentation capacity and 
produce immunosuppressive cytokines IL-10 and TGF-β (Muenst et al., 2016). 
Myeloid derived suppressor cells (MDSC) are immature cells with potent 
immunosuppressive features detected in tumors of murine models and patients 
with different types of tumors. In mice, MDSCs are defined by the co-expression 
of macrophage (CD11b+) and neutrophil (Gr1+) markers, but in humans, their 
characterization is more complex since human MDSCs are comprised of 
populations with diverse phenotypes  (Spano and Zollo, 2012). The MDSCs can 
be distinguished as either monocytic (M-MDSC), that are more like monocytes, or 
polymorphonuclear (PMN-MDSC), resembling neutrophils. M-MDSCs have 
stronger immunosuppressive capabilities than PMN-MDSCs which explains why 
M-MDSCs are abundant in tumors (Kumar et al., 2016). The MSDCs have different 
mechanisms to disturb immunosurveillance and orchestrate immunosuppression 
in the TME. The MDSCs impair T cell activity by the expression of arginase (ARG-
1). Arginase consumes L-arginine and the depletion of this essential amino acid 
from the TME causes downregulation of T cell receptor complex and proliferative 
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arrest. The expression of iNOS enzyme by MDSCs creates oxidative stress which 
also affects T cell function (Gabrilovich, Ostrand-Rosenberg and Bronte, 2012). 
Myeloid derived suppressor cells also prevent M1 polarization (Sinha, Clements 
and Ostrand-Rosenberg, 2005) and disrupt NK cell cytotoxicity (Liu et al., 2007). 
Moreover, MDSCs promote the conversion of naïve CD4+ T cells into Tregs as well 
as their expansion, and these processes might be dependent on the production of 
immunosuppressive cytokines interleukin-10 (IL-10) and transforming growth 
factor β (TGF-β) (Huang et al., 2006).  
Regulatory T cells (Tregs) are immunosuppressive cells that during 
homeostasis prevent excessive immune responses and promote self-tolerance, 
but in the context of tumorigenesis, Tregs may allow the escape of tumor cells from 
immunosurveillance (Lee, 2017). The association of Tregs with patient outcome is 
very controversial. In many cancers, including melanoma, the accumulation of 
Tregs is correlated with poor prognosis (Knol et al., 2011). Conversely, when tumor 
initiation is associated with chronic inflammation (i.e., colorectal cancer) Tregs 
have a protective effect and therefore high numbers of this immunosuppressive 
cell predicts improved survival (Frey et al., 2010). Treg cells exert their repressive 
role onto tumor-specific lymphocytes via a variety of mechanisms including 
production of immunosuppressive cytokines IL-10 and TGF-β, eliminating IL-2 
which is an essential cytokine for CTLs expansion and expressing the immune 
checkpoint inhibitor CTLA-4, a common target in immunotherapy (Schreiber, Old 
and Smyth, 2011). 
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1.2.1.3. Non-immune stromal cells 
Cancer-associated fibroblasts (CAFs) are the pioneer cells recruited to the 
TME and the most numerous cell population in the tumor stroma (Spano and Zollo, 
2012). CAFs, sometimes referred as myofibroblasts, are different from normal 
fibroblasts and detectable by the expression of α-smooth muscle actin (α-SMA) 
(Egeblad, Nakasone and Werb, 2010). The origin of CAFs present in the TME is 
still unclear. Some findings have suggested that fibroblasts may arise after 
epithelial cells experience epithelial-to-mesenchymal transition (EMT) (Petersen et 
al., 2003), whereas another study presented the possibility of endothelial cells 
generating fibroblasts after undergoing endothelial-to-mesenchymal transition 
(EndMT) (Zeisberg et al., 2007). Co-culture of cancer cells with normal fibroblasts 
or CAFS has demonstrated that CAFs are important for tumor initiation (Olumi et 
al., 1999) and invasive phenotype (Dimanche‐Boitrel et al., 1994). Cancer-
associated fibroblasts have many secretory functions that promote tumor growth 
and are considered the main source of growth factors in the TME (Quail and Joyce, 
2013). For example, hepatocyte growth factor (HGF) derived from CAFs provides 
the oncogenic signal for tumor cell proliferation. In addition, CAFs modify the ECM 
though the secretion of many ECM components (tenascin C, collagen I and II) as 
well as matrix metalloproteinases (MMPs) accelerating tumor progression (Kalluri 
and Zeisberg, 2006). Furthermore, CAFs modulate the recruitment of different 
populations of immune cells to the TME and ablation of CAFs from the TME 
reduces the amounts of TAMs, MDSCs and Tregs (Liao et al., 2009). Cancer-
associated fibroblasts are also an important supplier of vascular endothelial growth 
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factor  (VEGF) which underscores the pivotal function of fibroblasts during tumor 
angiogenesis (Fukumura et al., 1998). 
Endothelial cells are also a critical cellular component of the TME. Besides their 
vascular function in supplying nutrients to the TME, they have the capacity to 
create new routes for recruitment of immune cells and metastatic cells dispersion 
(Smith and Kang, 2013). Pro-angiogenic factors induce the sprouting of new 
vessels from existing ones in a process known as angiogenesis (Fang and 
DeClerck, 2013). In the earlier 1970s it was proposed that tumor development 
relies on angiogenesis (Sherwood, Parris and Folkman, 1971) and since then 
angiogenesis has been considered a hallmark of cancer (Hanahan and Weinberg, 
2011). Vascular endothelial growth factor is the major regulator of angiogenesis 
and its production in the TME results in endothelial cell migration and proliferation 
as well as increased vascular permeability (Hida et al., 2018). Tumor endothelial 
cells (TECs) are very different from their normal counterparts in many 
characteristics including gene expression profiles, chromosomal abnormalities and 
proliferative and migratory features (Maishi and Hida, 2017). Tumor endothelial 
cells from tumors with different metastatic potential are also distinct suggesting 
that endothelial cells are involved in  metastasis formation (Ohga et al., 2012). 
When TECs derived from highly metastatic tumors are co-injected with poorly 
metastatic cancer cells the metastatic potential of these tumor cells is enhanced 
(Maishi et al., 2016).  
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 Cytokines 
The different cell populations present in the TME establish a complex 
communication network and much of the cross-talk is regulated by cytokines that 
promote tumor growth and progression (Burkholder et al., 2014). The term cytokine 
was primarily used to describe the group of secreted molecules derived from 
hematopoietic cells. A sophisticated concept suggests that cytokines are 
molecules produced by a variety of cell types and used for cell-to-cell 
communication. These molecular messengers are major modulators of many 
physiologic and pathologic events including hematopoiesis, immune response, 
angiogenesis, wound healing and cancer (Huang et al., 2012). There are two 
fundamental features of cytokines that influence their microenvironmental action. 
Cytokines are pleiotropic molecules meaning that the same cytokine can produce 
diverse effects in different cell types. Cytokines are also redundant molecules, thus 
the action of different cytokines may have the same outcome in a cell population 
(Ozaki and Leonard, 2002). 
Cytokines play a decisive role during the polarization and biological action of 
some immune cells present in the TME. An integrated system of cytokines 
educates neutral and immature immune cells towards tumor-inhibitory or tumor-
promoting effector phenotypes. Tumor microenvironment education is a 
consequence of intrinsic plasticity of immune cells under the influence of 
stimulatory or suppressive cytokines (Quail and Joyce, 2013). Macrophages and 
CD4+ T cells are particularly susceptible to this molecular communication and in 
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response to cytokines existing in the TME they differentiate into either anti-
tumorigenic or pro-tumorigenic subtypes (Burkholder et al., 2014).  
Macrophage polarization has been well-described in many studies. Monocytes, 
the precursors of macrophages, are very sensitive to the first cytokines they 
encounter in the TME (Figure 1.3). Upon arrival in the TME, if monocytes are 
initially exposed to the cytokine IFN-γ they differentiate into M1 macrophages 
(Grivennikov, Greten and Karin, 2010). Macrophages M1 secrete many pro-
inflammatory cytokines, namely IL-1, IL-6, IL-12, and TNF-α (Rhee, 2016). 
Conversely, if after arriving in the TME monocytes first encounter the cytokines IL-
4, IL-10, IL-13 or TGF-β (Allavena et al., 2008) they are polarized towards M2 
phenotype and produce anti-inflammatory cytokines TGF-β and IL-10 (Sica, 
Allavena and Mantovani, 2008). Macrophage phenotype is very plastic therefore it 
is also possible that, as a result of cytokine re-education, M2 macrophages switch 
towards M1 phenotype (Quail and Joyce, 2013).  
The CD4+ helper T cells can be distinguished into many subtypes depending 
on their cytokine profile (Figure 1.4). The differentiation of naïve CD4+ T cell into 
effector subsets found in the TME is orchestrated by APC-derived cytokines during 
antigen presentation. Remarkably, the specific cytokines of a subgroup can 
reinforce its differentiation while prevent the differentiation into a different subtypes 
(Gutcher and Becher, 2007). Initially, it was believed that naïve CD4+ T cells would 
only be able to polarize towards either TH1 or TH2. When APCs present antigen to 
naïve CD4+ T cells in presence of IL-12, TH1 cells are generated (Seder et al., 
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1993) and TH1 cells will prominently secrete IFN-γ in addition to TNF-α, IL-2 and 
IL-12 cytokines (Burkholder et al., 2014). On the other hand, if there is no IL-12 
during antigen presentation, naïve CD4+ T cells start to secrete IL-4 and 
differentiate into TH2 cells (Swain et al., 1990), which in addition to IL-4 also 
produce IL-5 and IL-10 cytokines (Moss et al., 2004). Later it was discovered that 
TGF-β is also an important regulator of naïve CD4+ T cell polarization. Secretion 
of TGF-β alone by APC generates the immunosuppressive subtype Treg that 
produces IL-10 and TGF-β (Chen et al., 2003). However, when TGF-β is 
supplemented with IL-6, naive CD4+ T cells polarize towards the pro-inflammatory 
subtype TH17 which produces IL-17 (Veldhoen et al., 2006). The TH17 cells 
execute their anti-tumor actions recruiting more CTLs, NKs and DCs to the TME 
(Nagarsheth, Wicha and Zou, 2017). 
A cytokine network comprised of the canonical pro-inflammatory cytokines IL-
1, IL-6, and TNF-α as well as TH1-associated cytokines IL-12 and IFN-γ 
coordinates the effective anti-tumor immune response accountable for tumor 
immunosurveillance (Figure 1.5). Tumor-specific TH1 cells produce the 
proliferative cytokine IL-2 in addition to IFN-γ, a cytokine that polarizes 
macrophages towards M1 phenotype. Polarized M1 macrophages secrete IL-12, 
that enhances TH1 phenotype, and also a series of pro-inflammatory cytokines 
(i.e., IL-1, IL-6 and TNF-α) that have tumoricidal activity (Haabeth, Bogen and 
Corthay, 2012). Interleukin-1 cooperates with IL-2 to promote proliferation of CTLs 
and NK cells (Aribia et al., 1987) and enhances the antigen-presenting functions 
of DCs (Burkholder et al., 2014). Interleukin-6 increases CD4+ and CTL anti-tumor 
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activity and prevents tumor progression (Mulé et al., 1992). Tumour necrosis factor 
α (TNF-α) is crucial for NK recruitment to the TME and mice lacking TNF-α have 
defective tumor immunosurveillance (Smyth et al., 1998). Additionally, M1 
macrophages produce chemokines CXCL9, CXCL10 and CXCL11 that attract 
more anti-tumorigenic cells to the TME (Haabeth, Bogen and Corthay, 2012). 
Cytokines participate in the conversion from tumor-inhibitory to tumor-
promoting TME. The balance shifted towards anti-inflammatory cytokines rather 
than pro-inflammatory cytokines creates an immunosuppressive milieu that allows 
escape from tumor immunosurveillance (Burkholder et al., 2014). Interleukin-10 
and TGF-β produced by different cell populations are the two major regulators of 
immunosuppression in the TME (Figure 1.6) (Kim et al., 2006).  
Interleukin-10 is an immunosuppressive cytokine that allows escape of tumor 
cells from immune destruction in the TME (Mannino et al., 2015). High expression 
of IL-10 is considered a poor prognostic factor for patients with melanoma 
(Dummer et al., 1995; Nemunaitis et al., 2001). Type 2 lymphocytes (TH2) seem to 
be the main source of IL-10 in the TME, but other cells types including Tregs, 
TAMs, DC, NK and tumors cells also produce IL-10. The major mechanism of IL-
10 immunosuppression is the impairment of antigen presentation (Sato et al., 
2011). Interleukin-10 downregulates co-stimulatory (B7) (Ding et al., 1993) and 
MHC molecules of APCs (de Waal Malefyt et al., 1991). Interleukin-10 also induces 
immunosuppressive activity of Tregs and suppresses pro-inflammatory TH17 cells 
(Oft, 2014). Further, in vitro studies have shown that IL-10 turns CTLs 
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unresponsive to antigens (Groux et al., 1998) and inhibits the production of IFN-γ 
cytokine in TH1 (Taga and Tosato, 1992) and NK cells (Peppa et al., 2010). Some 
studies have  challenged the paradigm that IL-10 exclusively supports tumor 
development. In some contexts, IL-10 may play anti-tumorigenic roles by 
increasing the proliferation of CTLs (Chen and Zlotnik, 1991) and NK cell cytotoxic 
activity (Parato et al., 2002).  
Similar to the ambiguous role of  IL-10, the role of immunosuppressive cytokine 
TGF-β in tumor development is also paradoxical and context-dependent. Early in 
tumorigenesis TGF-β prevents tumor formation by supporting apoptosis and 
inhibiting cell cycle progression. During late stages of tumor formation TGF-β 
promotes invasion and immunosuppression (Landskron et al., 2014). Many cell 
populations secrete TGF-β in the TME including the cancer cells, macrophages, 
MDSCs, lymphocytes, fibroblasts and endothelial cells (Massagué, 2008). Overall, 
TGF-β in the TME suppresses the development, proliferation, and function of anti-
tumorigenic cells (Pickup, Novitskiy and Moses, 2013). Mice with defects in the 
TGF-β signaling pathway develop benign neoplasia associated with inflammation 
that eventually evolves to malignant tumors (Engle et al., 2002).  The most notable 
feature of TGF-β in the TME is to polarize macrophages towards M2 phenotype 
(Gong et al., 2012). The suppression of TH1 response and T cell proliferation is 
also mediated by TGF-β signaling (Gorelik, Constant and Flavell, 2002). 
Transforming growth factor β inhibits the antitumor response of CTLs (Thomas and 
Massagué, 2005) as well as impairs the maturation of NK (Marcoe et al., 2012) 
and DCs, which otherwise would be able to detect cancer cells and initiate the 
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tumor clearance process (Novitskiy et al., 2012). Lastly, TGF-β induces the 
differentiation of naïve CD4+ cells into Treg, a very immunosuppressive subtype 
that in addition to suppression of immune response also produces TGF-β (Chen 
et al., 2003). 
Chemokines constitute a subgroup of cytokines responsible for the recruitment 
of immune cells along the concentration gradient of a ligand, a process known as 
chemotaxis. Chemokine receptors belong to the G-protein coupled receptor 
(GPCR) family of receptors and bind to more than one type chemokine ligand. 
Chemokines are divided into four groups (CXC, CC, C, CX3C) determined by the 
position of the first two cysteine residues in their protein sequence (Balkwill, 2004). 
The trafficking of immune cells to the TME is mediated by combinations of different 
chemokines. Hence, chemokines are considered important regulators of anti-
tumor immunity and immune detection escape (Amedei, Prisco and M. D’Elios, 
2013). Tumor-inhibitory cells CTLs, NK and TH1 cells express the chemokine 
receptor CXCR3 and are intensively recruited to the TME in response to 
chemokine ligands CXCL9, CXCL10, and CXCL11 (Nagarsheth, Wicha and Zou, 
2017). The DCs expressing CCR6 migrate to the TME in response to CCL20 
produced by tumor cells (Bell et al., 1999). Recruitment of macrophages to tumors 
is mainly governed by CCR2-CCL2 (Qian et al., 2011) and CCR5-CCL5 
chemokine axes (Azenshtein et al., 2002). Regulatory T cells expressing CCR4 
are recruited to the TME by CCL22 derived from tumor cells and macrophages 
(Curiel et al., 2004). The main chemokines attracting M-MDSCs to the tumors are 
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CCL2 and CCL5. PMN-MDSCs rely on chemokines CXCL5, CXCL6 and CXCL8 
to find their way to the TME (Kumar et al., 2016).  
Recently, immunotherapy approaches targeting only a single chemokine axis 
have failed to produce satisfactory results in patients with chronic inflammatory 
diseases. The therapeutic failure probably happened as a result of the pleiotropic 
effect of chemokines. In the context of cancer, targeting a specific chemokine axis 
is most certainly affecting different population of cells in the TME. Thus, 
combinatorial strategies aiming to simultaneously stimulate anti-tumor and silence 
pro-tumor chemokines axes could potentially achieve meaningful results 
(Nagarsheth, Wicha and Zou, 2017).    
 Melanoma Microenvironment 
The strong interaction between tumorigenic cells and all other cell types in the 
TME sustain melanoma development (Passarelli et al., 2017). At normal conditions 
the proliferation of melanocytes is firmly regulated by keratinocytes through the 
expression of adhesion molecules. During tumorigenesis melanoma cells 
circumvent the microenvironmental regulation of proliferation by downregulating E-
cadherin and overexpressing N-cadherin. The expression of N-cadherin also 
mediates the interaction of melanoma cells with fibroblasts and endothelial cells in 
the TME (Villanueva and Herlyn, 2008). A paracrine loop relying on growth factors 
supports the proliferation of both melanoma cells and fibroblasts in the TME. 
Melanoma cells secrete platelet-derived growth factor (PDGF) and fibroblast 
growth factor (FGF) that stimulate fibroblasts to proliferate and to secrete growth 
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factors insulin-like growth factor 1 (IGF-1) and HGF, further supporting melanoma 
cell proliferation (Melnikova and Bar-Eli, 2009).  
Melanoma has long been recognized as one of the most immunogenic types 
of tumor, having the capacity to elicit strong anti-tumor responses (Passarelli et 
al., 2017). Melanoma associated antigens such as melan-a, gp100, and tyrosinase 
can be detected by T cells and trigger tumor-specific immune responses (Castelli 
et al., 2000). The UV-induced high somatic mutation burden in melanoma creates 
TAA that can be detected by immune cells (Wang et al., 2017). As such, 
melanomas with high mutation load have good response to immunotherapies 
(Ejeta et al., 2015). Recent findings have suggested that melanoma arises in a 
chronic inflammatory environment (Umansky and Sevko, 2012). Oncogenic 
signals are important not only for tumor cells’ deregulated proliferation but also for 
creating an inflammatory milieu. Forced expression of BRAFV600E in normal 
melanocytes results in the production of IL-1 and IL-6 (Kuilman et al., 2008). 
Expression of pro-inflammatory cytokines IL-1, IL-6, and TNF-α are upregulated 
when nevi are compared to thick primary melanomas (Moretti et al., 1999). 
Additionally, melanoma cells express a variety of chemokines ligands including 
CCL2, CCL5, CXCL1-3, CXCL5-8, and CXCL10 that recruit different populations 
of immune cells to the TME (Richmond, Yang and Su, 2009).  
Although remarkably immunogenic, melanoma develops a variety of strategies 
to circumvent immune detection. Melanoma cells downregulate MHC-I molecules 
impairing cytotoxic T cell activity (Ferrone and Marincola, 1995). Melanoma cells 
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do not display the ligands for NK cell activating receptors on their surface, allowing 
them to escape NK destruction (Fuertes et al., 2008). Melanoma cells express PD-
L1, the ligand to the immune checkpoint PD-1, suppressing melanoma-specific 
CTLs (Yang et al., 2008). The expression level of PD-L1 in melanoma tumors is 
positively correlated with aggressiveness (Hino et al., 2010).  The melanoma 
genotype is also associated with the impairment of anti-tumor immune response 
in the TME (Binnewies et al., 2018). In addition to inflammatory cytokines, 
BRAFV600E expression in melanoma cells drives the production of 
immunosuppressive cytokine IL-10 contributing to the evasion of immune 
detection (Sumimoto et al., 2006). Melanocytic expression of BRAFV600E and β-
catenin coupled with Pten deletion in a mouse model generated aggressive 
melanomas that were poorly infiltrated by CTLs because of the lack of DCs in the 
TME. The expression of β-catenin in melanoma cells reduces the availability of 
CCL4 chemokines, which in turn diminishes the trafficking of DCs to the 
microenvironment (Spranger, Bao and Gajewski, 2015).  
Undoubtedly, immune cells are central players of immunosuppression in the 
melanoma microenvironment. The seminal work by Tirosh and colleagues 
expanded our understanding about the immune cells in the melanoma TME. The 
authors performed single-cell RNA sequencing (RNA-Seq) of 4645 malignant and 
non-malignant cells from 19 patients with metastatic melanoma to establish the 
profile of stromal cells in the melanoma TME. They showed that the melanoma 
ecosystem is consisted mainly of T (CD8+, CD4+ and Treg) and B lymphocytes. In 
addition, there are other immune populations, namely macrophages and NK cells 
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and stromal cells including CAFs and endothelial cells. In the T cell infiltrate of 
metastatic melanomas, CTLs express cytotoxic genes together with exhaustion 
markers PD-1 and CTLA-4. Furthermore, clonal expanded CTLs show signs of 
exhaustion indicating the suppression of immune surveillance. Tregs represent a 
small population of lymphocytes (57 out of 2068 cells) in TME. These 
immunosuppressive cells overexpress immune checkpoint CTLA-4 and have a 
moderate to low expression of cytotoxic marker GZB (Tirosh et al., 2016). 
Transforming growth factor β is central to the Tregs mediated immunosuppression 
in the melanoma TME. In addition to inhibiting cytotoxic T cell functions and APCs, 
TGF-β also promotes Treg proliferation (Braeuer et al., 2014). Accordingly, these 
data strongly suggest that melanoma is a type of “cold” tumor, thus in the 
melanoma TME there are few activated CTLs and many immunosuppressive cells 
preventing anti-tumor cytotoxic activity (Binnewies et al., 2018).  
The intense research on melanoma microenvironment has paved the way for 
the development of immunotherapies that have recently revolutionized the 
management of melanoma disease producing long-lasting successful responses 
(Giavina-Bianchi, Giavina-Bianchi Junior and Festa Neto, 2017). Melanoma 
immunotherapy has been particularly focused on the employment of immune 
checkpoint inhibitors anti-CTLA-4 and anti-PD-1, in order to rescue activation and 
function of tumor-specific lymphocytes, respectively (Binnewies et al., 2018). 
Cytotoxic T lymphocyte associated protein 4 (CTLA-4) is an inhibitory molecule 
expressed by activated T cells that competes with co-stimulatory receptor CD28 
for the B7 ligand expressed on the surface of DCs. CTLA-4 normally works as a 
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molecular brake during the priming of T cells preventing excessive T cell 
responses (Postow, Callahan and Wolchok, 2015). Preclinical studies blocking 
CTLA-4 generated effective response against tumors (Leach, Krummel and 
Allison, 1996) and encouraged the development of clinical trials using human 
CTLA-4 blocking antibody (ipilimumab). Although preliminary studies had shown 
that ipilimumab might have an initial delayed response associated with disease 
progression (Saenger and Wolchok, 2008), CTLA-4 blockage in patients with 
metastatic melanoma have produced an astonishing durable response for up to a 
decade (Schadendorf, Hodi, et al., 2015). Ipilimumab was found to be more 
effective than conventional chemotherapy in the treatment of patients with 
advanced melanomas (Robert et al., 2011).  
Targeting the PD-1 pathway using nivolumab or pembrolizumab blocking 
antibodies is another very effective immunotherapy approach that has achieved 
long-term satisfactory results in patients with metastatic melanoma (Topalian et 
al., 2014). Programed cell death-1 (PD-1) is a negative regulator expressed by 
exhausted CTLs during chronic immune response in the TME. Binding of PD-L1 
expressed on the surface of tumor cells to the PD-1 receptor present in CTLs 
inactivates immune responses against tumors (Ribas and Wolchok, 2018). A 
possible explanation for the successful blockage of PD-1 pathway is the presence 
of infiltrated tumor-specific CTLs in the TME (Haanen, 2017). An effective strategy 
to convert “cold” melanomas into highly inflamed tumors is through intratumoral 
injection of oncolytic virus. This procedure induced CTLs infiltration into the TME 
and, after the treatment with pembrolizumab, resulted in reduction of tumor burden 
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in more than 60% of patients with metastatic melanoma (Ribas et al., 2017). The 
immune checkpoints CTLA-4 and PD-1 have temporal and spatial distinct 
mechanisms of action. Cytotoxic T lymphocyte associated protein 4 regulates the 
initial steps of immune response in the draining lymph node whereas PD-1 controls 
the effector phase of immune response in the TME. These observations suggest 
that combination of CTLA-4 and PD-1 immune checkpoints inhibitors would have 
synergetic effects in the immune response against tumors (Postow, Callahan and 
Wolchok, 2015; Ribas and Wolchok, 2018). In fact, melanoma patients treated with 
pembrolizumab in combination with ipilimumab presented considerable longer 
durable response rate when compared to monotherapy (Larkin et al., 2015). 
In the last few years, a great body of data have shown that the gut microbiota 
is an important modulator of melanoma response to immunotherapy and can be 
manipulated to provide better clinical responses (Vancheswaran Gopalakrishnan 
et al., 2018). Anti-CTLA-4 treatment changed the diversity of microbiota in mice, 
specifically decreasing the amount of Bacteroidales and increasing Clostridiales 
load in the gut. Germ-free mice treated with anti-CTLA-4 did not exhibit anti-tumor 
response, which was reestablished when mice received immune checkpoint 
inhibitor in combination with Bacteroidales isolates. Furthermore, fecal microbiota 
transplantation (FMT) from melanoma patients with high amounts of Bacteroidales 
enhanced the anti-tumor effect of CTLA-4 blockage in mice (Vetizou et al., 2015). 
Interestingly, mice from different vendors but with the same genetic background 
responded differently to PD-1 pathway blockage. The determinant of the distinct 
response was the amount of Bifidobacterium in the microbiota. Mice with more 
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Bifidobacterium in the gut showed delayed melanoma growth when treated with 
anti-PDL-1. When mice with low amounts of Bifidobacterium were treated with 
these bacteria they presented improved anti-tumor response to PD-L1 blockage. 
Bifidobacterium positively influences DCs function and consequently improves 
anti-tumor activity of CTLs (Sivan et al., 2015). Recently, these findings were 
shown to have clinical relevance for patients with metastatic melanoma (Jobin, 
2018). As observed in the preclinical studies, melanoma patients responding (R) 
to PD-1 blockage had distinct microbiota profile compared to those not responding 
(NR) to treatment. Favorable microbiota augmented the number of APCs and 
CTLs in the TME as well as the frequency of CTLs compared to Tregs. Mouse 
models validated these observations and confirmed that FMT from R melanoma 
patients to germ-free mice was able to improve anti-tumor response to anti-PD-1 
treatment (Matson et al., 2018; V. Gopalakrishnan et al., 2018). 
1.3. Endothelin 
Endothelin (Edn) is a cytokine ubiquitously expressed in various organs and 
has remarkable pleiotropic functions. There are 3 isoforms of endothelins - Edn1, 
Edn2, and Edn3 - that bind to 2 different GPCRs, endothelin receptor type A 
(Ednra) and type B (Ednrb). Endothelin 1 is the predominant and more relevant 
isoform and binds with the same affinity to both Ednra and Ednrb. Edn2 also has 
similar affinity to Ednra and Ednrb whereas Edn3 is very selective for Ednrb 
(Aubert and Juillerat-Jeanneret, 2016). Binding of endothelin to one of its cognate 
receptors triggers the stimulation of a variety of downstream effectors (Rosanò, 
Spinella and Bagnato, 2013). Activation of endothelin receptor initiates PLCβ 
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signaling pathway resulting in PKC activation (Simonson and Dunn, 1990). 
Endothelin receptors activate MAPK and PI3K pathways leading to ERK 
phosphorylation (Iwata et al., 2009) and mTOR activation (Wu et al., 2012). 
Different cell types secrete endothelins including endothelial cells, 
cardiomyocytes, leukocytes, glial cells and epithelial cells in the lung and kidney. 
Equally diverse is the roster of cell populations that express receptors to endothelin 
and includes among others, endothelial and smooth cells, neurons, hepatocytes, 
adipocytes, keratinocytes, and melanocytes (Khimji and Rockey, 2010). Of note, 
the expression pattern of each endothelin varies regarding organs and cell types 
(Masaki, 2004). 
 Endothelin Physiology and Pathology 
Endothelins were first discovered as mediators of vascular function 
(Yanagisawa et al., 1988). Endothelial cells secrete Edn1 that binds to the Ednra 
expressed on smooth cells and trigger vasoconstriction. Endothelin 1 is considered 
to be the most potent vasoconstrictor already described. Endothelin 1 derived from 
endothelial cells can also bind to Ednrb expressed by neighboring endothelial cells. 
Stimulation of Ednrb in endothelial cells induces the secretion of nitric oxide (NO), 
a strong vasodilator for smooth cells (Kawanabe and Nauli, 2011). Endothelins 
have many other physiological functions besides vasoconstriction. For example, 
endothelins regulate development of neural crest cells (Kedzierski and 
Yanagisawa, 2001) bronchoconstriction in the lungs (Uchida et al., 1988) and 
water and salt excretion in the kidneys (Kohan, 2006). Shortly after endothelin 
discovery, a variety of pathological conditions were found to be associated with 
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alterations in endothelin physiology. Cardiovascular diseases including 
hypertension and atherosclerosis, pulmonary arterial hypertension and 
glomerulosclerosis are all diseases that have an inflammatory component 
associated with deregulation in endothelin signaling suggesting that endothelin 
modulates immune system functions (Barton and Yanagisawa, 2008). 
The inflammatory process involves changes in the vascular permeability and 
trafficking of leukocytes to the sites of tissue injury. Endothelin is associated with 
these events and therefore, is considered a pro-inflammatory cytokine (Figure 1.7) 
(Nett et al., 2006). The transcription factor NF-κB, a central regulator of 
inflammation, is under the control of endothelin signaling (Wilson, Simari and 
Lerman, 2001). Endothelin increases local vascular permeability (Filep et al., 1992) 
and stimulates the expression of adhesion molecules (i.e., ICAM-1) on endothelial 
cells (Hayasaki et al., 1996), allowing the infiltration of leukocytes into the 
inflammation site. Endothelin in the inflammatory milieu stimulates neutrophil 
accumulation (López Farré et al., 1993) and is a chemoattractant for monocytes 
(Hanggono Achmad and Rao, 1992), and macrophages. Of note, the chemical 
structure of mature endothelins resembles that of some chemokines (Grimshaw, 
Wilson and Balkwill, 2002). Secretion of pro-inflammatory cytokines IL-1, IL-6, 
TNF-α, and IFN-γ is regulated by endothelin expression (Yang et al., 2004). 
Interestingly, activated T cells produce TNF-α and IFN-γ inducing monocytes to 
secrete endothelin, which in turn enhances the inflammatory process (Shinagawa 
et al., 2017). In addition to endothelial cells and monocytes, DCs (Guruli et al., 
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2004) and macrophages (Ehrenreich et al., 1990) are other sources of endothelin 
in the inflammatory environment.  
 Endothelin signaling in melanocytes and melanoma cells  
Many cytokines are associated with melanocyte and melanoma biology, among 
them are the endothelins. The Edn3/Ednrb pathway has been implicated in 
melanocyte development as well as melanoma progression (Saldana-Caboverde 
and Kos, 2010). Endothelin 3 regulates the proliferation and survival of melanocyte 
precursors (Lahav et al., 1996, 1998) and promotes melanoblast differentiation into 
melanocytes (Reid et al., 1996). The essential role of endothelin signaling during 
melanocyte development is demonstrated by mouse models with spontaneous 
mutations in Edn3 (Baynash et al., 1994) and Ednrb genes (Hosoda et al., 1994). 
These mice have hypopigmented phenotypes because of the reduction in the 
number of melanoblasts and impaired migration of melanocyte precursors during 
development (Pavan and Tilghman, 1994; Lee, Levorse and Shin, 2003). 
Conversely, overexpression of Edn3 in the mouse skin leads to an augmented 
melanoblast population and a hyperpigmented phenotype (Garcia et al., 2008). 
The communication between keratinocytes and melanocytes is mediated by 
endothelin. Upon UV light exposure, keratinocytes release Edn1 (Imokawas, Yada 
and Miyagishi, 1992) that stimulates melanin production in the melanocytes 
(Imokawa et al., 1997). Thus, endothelin may have an indirect protective effect 
against melanoma initiation (Saldana-Caboverde and Kos, 2010).  
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Initially, EDNRB was thought to be expressed at low levels in melanoma cells. 
Profiling of a cDNA library detected the downregulation of EDNRB in 16 out of 17 
human melanoma cells lines (Eberle et al., 1999). Analysis of primary and 
metastatic melanoma cell lines reported that EDNRB is downregulated when 
metastatic cells are compared to primary melanoma (Kikuchi et al., 1996). Further 
studies including human samples challenged the in vitro findings and showed that 
EDNRB expression increases during melanoma progression. A gene profiling 
study of melanoma cell lines and tumor biopsies showed that EDNRB is 
overexpressed in most of human melanomas (Bittner et al., 2000). Demunter et al. 
(2001) demonstrated that EDNRB expression gradually increases from benign 
nevi to metastatic melanoma and proposed ENDRB as marker  for melanoma 
progression (Demunter et al., 2001). Tang et al. (2008) were the first to address 
the role of EDN3 on melanoma progression. The analysis of biopsies and cell lines 
revealed that metastatic melanoma cells express high levels of EDN3 suggesting 
that its autocrine secretion might modulate melanoma metastasis (Tang et al., 
2008). Using human samples and a mouse model of melanoma brain metastasis, 
Cruz-Munoz et al. (2012) showed that the overexpression of EDNRB promotes 
melanoma metastatic growth within the central nervous system (CNS) (Cruz-
Muñoz et al., 2012). The proliferation of metastatic melanoma cells in the brain 
might take place as a result of EDNRB interaction with EDN3 since this ligand is 
abundant in the CNS (Davenport et al., 2016). Additional studies demonstrated 
that Ednrb activation triggers many molecular events relevant for melanoma 
metastasis. Binding of EDN1 or EDN3 to EDNRB downregulates E-cadherin 
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(Jamal and Schneider, 2002) and increases the expression of N-cadherin and as 
well as secretion of MMPs. Endothelin Receptor B activation also stimulates 
proliferation, migration, and invasion of melanoma cells (Bagnato et al., 2004). 
Altogether, these findings strongly suggest that the Ednrb/Edn3 axis contributes 
significantly to melanoma progression. Figure 1.8 summarizes the effects of 
endothelin signaling in melanoma cells.  
As discussed above a well-established body of data establishes that EDNRB 
plays tumor-promoting roles during melanoma development. Conversely, few 
studies have addressed the tumor suppressive aspects of EDNRB. These reports 
suggest that, in some specific contexts, EDNRB can act as a tumor suppressor 
gene preventing melanoma initiation. In the RET transgenic mouse model of 
melanoma, Ednrb expression is reduced when malignant tumors are compared to 
benign melanocytic lesions. Furthermore, RET transgenic mice carrying a 
heterozygous deletion of Ednrb (Ednrb+/-; RET-mouse) develops de novo 
melanomas that are more prone to metastasize to the lungs compared to RET-
mouse (Kumasaka et al., 2010). Additional studies using the same mouse model 
revealed that the reduction of Ednrb levels is associated with Plexin 
downregulation. Plexin is considered a melanoma tumor suppressor (Scott et al., 
2009) and the positive correlation between Ednrb and Plexin expression supports 
a possible tumor suppressive role of Ednrb (Kumasaka et al., 2015). Variants in 
the EDNRB gene might underscore the tumor suppressive effect of EDNRB. 
Berger et al. (2006) demonstrated that EDN1 had reduced binding to an EDNRB 
variant found in a human melanoma cell line. This EDNRB variant is probably 
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defective in the N- and C- terminal domains making the receptor unable to bind to 
endothelins (Berger, Bernasconi and Juillerat-Jeanneret, 2006). 
The relevance of EDNRB variants for melanoma incidence is still under debate. 
Caucasians harboring the germline variant S305N in the EDNRB gene are 
associated with increased predisposition to melanoma (Soufir et al., 2005). 
However, two case-control studies, one in Germany (Thirumaran et al., 2006) and 
another in Spain (Fernandez et al., 2009) claimed that S305N variant is not 
associated with melanoma risk. The Spanish study took in consideration only 
sporadic melanoma cases. Still, some reports have linked EDNRB mutation with 
familial melanoma. A study with 2 independent large populations of Caucasians 
showed that S305N variant in EDNRB gene is not linked with sporadic melanoma 
but is significantly associated with CDKN2A mutations, which is responsible for 
familial melanoma. Therefore EDNRB variants might be important players of 
inheritably susceptibility to melanoma (Spica et al., 2011).  
 EDNRB and melanoma: clinical opportunities 
Notwithstanding the recent advances regarding targeted therapy and 
immunotherapy, melanoma treatment still faces many challenges. Clinical 
targeting of EDNRB emerges as a very promising approach despite the 
paradoxical findings. The most explored strategy is to block EDNRB using 
bosentan, a dual antagonist to EDNRA/EDNRB, or antagonist selective for EDNRB 
such as BQ788, A-192621. Some of these inhibitors are routinely employed for 
treating cardiovascular or pulmonary dysfunctions and their therapeutic features 
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have been assessed in the context of melanoma (Aubert and Juillerat-Jeanneret, 
2016). Most of the data exploring blockage of endothelin signaling in melanoma 
came from studies using cell lines and preclinical mouse models (Lahav, Heffner 
and Patterson, 1999; Rosanò et al., 2004; Smith et al., 2017). Clinical trials aiming 
to block EDNRB in patients with melanoma demonstrated limited beneficial results 
and therefore might require additional investigation (Kefford et al., 2007; Wouters 
et al., 2015). 
The endothelin receptor inhibitor BQ-788 very efficiently competes with EDN1 
for EDNRB, but not EDNRA, and is considered the strongest EDNRB antagonist 
(Ishikawa et al., 1994). Melanoma cell lines exposed to BQ-788 showed cell growth 
inhibition as well as enhanced cell death. The same effects were not observed 
when melanoma cells are treated with EDNRA selective inhibitor. Furthermore, 
BQ788 treatment abrogated tumor growth in melanoma xenografts (Lahav, 
Heffner and Patterson, 1999). The apoptotic effect of BQ-788 was more prominent 
in aggressive melanoma cells and relied on the reduction of survival factor BCL2A1 
expression associated with caspase-6 activation (Lahav et al., 2004). Bagnato and 
colleagues extensively explored the role of EDNRB blockage in melanoma. They 
showed that BQ-788 impairs the phosphorylation of ERK and decreases 
melanoma cell proliferation. BQ788 treatment also prevents upregulation of N-
cadherin, downregulation of E-cadherin as well as secretion of metalloproteinases 
(Bagnato et al., 2004).  
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Modifications on the chemical structure of EDNRA antagonists led to the 
development of the oral non-peptide selective EDNRB antagonist A192621 (von 
Geldern et al., 1999). Administration of A192621 to melanoma xenografts had 
remarkable tumor suppressor effects. The EDNRB antagonist A192621 abolished 
tumor cell proliferation as well as reduced tumor volume in nude mice (Bagnato et 
al., 2004; Spinella et al., 2007). Melanoma brain metastatic cell lines exhibited 
decreased cell proliferation when treated with A192621. Monotherapy with 
A192621 is infective in brain metastasis treatment because of the inability of 
A192621 to cross the blood-brain barrier (BBB). However, when A192621 
treatment was associated with inhibitors of efflux pump P-glycoprotein (PGP), the 
EDNRB inhibitor was able to penetrate the CNS and decrease the size of 
melanoma brain metastasis (Cruz-Muñoz et al., 2012). 
Tumorigenesis is highly dependent on the process of angiogenesis. 
Therapeutic inhibition of EDNRB has controversial effects in melanoma 
angiogenesis. The treatment with BQ-788 was shown to play a pro-angiogenic 
role. Melanoma cells treated with BQ-788 showed increased expression of VEGF 
and hypoxia-inducible factor-1α (HIF1α) and downregulation of the angiogenic 
suppressor gravin. It is possible that the increase expression of VEGF resulting 
from  EDNRB blockage encourages endothelial cells to proliferate (Lahav et al., 
2004). Patients treated with BQ-788 exhibited abundance of blood vessels and 
increased expression of HIF1α. Although angiogenesis is helpful for melanomas 
as it increases the blood supply, the formation of new blood vessels can also be 
harmful to tumors since they create new routes for immune cells to be recruited to 
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the TME (Wouters et al., 2015). Conversely, A192621 treatment seems to have 
evident anti-angiogenic effect in melanoma. Melanoma xenografts treated with 
A192621 presented increased PDH2 expression and downregulation of HIF1α, 
this in turn impaired angiogenesis and tumor growth (Spinella et al., 2007, 2010). 
Despite the successful anti-melanoma effect of EDNRB blockage in preclinical 
studies, the clinical relevance of this approach is still elusive. Bosentan is a non-
peptide dual EDNRA and EDNRB antagonist. Preclinical studies showed that this 
EDNRB inhibitor reduces cell viability and stimulates apoptosis in human 
melanoma cells. The apoptotic effect of bosentan is enhanced when it is combined 
with chemotherapy drug dacarbazine (DTIC) (Berger, Bernasconi and Juillerat-
Jeanneret, 2006). These results encouraged clinical trials that addressed the anti-
tumor effect of bosentan in patients with metastatic melanoma. A phase II clinical 
study showed that 6 out 32 patients with stage IV melanoma presented disease 
stabilization upon monotherapy with bosentan (Kefford et al., 2007). Unfortunately, 
in a supplementary study, the combination of bosentan with DTIC showed no effect 
in tumor progression and survival of patients with metastatic melanoma (Kefford 
et al., 2010). One of the potential reasons for the unsuccessful outcomes of 
EDNRB blockage in melanoma patients is the absence of previous screening for 
patients with high levels of intratumoral EDNRB. Blocking EDNRB using BQ788 
seems to be more effective for melanoma patients. A recent clinical study 
demonstrated that intralesional administration of the selective EDNRB antagonist 
directly reduced the expression of the proliferation marker Ki-67 as well as 
diminished tumor growth. Treatment with BQ-788 also enhanced immune cell 
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infiltration in melanoma, suggesting that future studies evaluating the efficacy of a 
combination of EDNRB inhibitor and immune checkpoint inhibitors should be 
carried out (Wouters et al., 2015).   
To overcome the low sensitivity of small molecule antagonists such as BQ-788, 
functional monoclonal antibodies (mAB) can also be used as therapeutic 
strategies. Rendomab-B1 was the first described mAb with antagonist ability to the 
human EDNRB. Rendomab-B1 exhibits dual pharmacological action, it competes 
with EDN1 ligand as well as promotes EDNRB internalization (Allard et al., 2013). 
Another approach that has been tested in melanoma is antibody-drug conjugated 
(ADC) therapy that combines antibodies with potent cytotoxic agents. Asundi and 
colleagues (2011) developed a monoclonal antibody (5E9) conjugated with the 
potent cytotoxic compound MMAE. The ADC 5E9 has high affinity to EDNRB and 
is rapidly internalized. Antibody-drug conjugated 5E9 shows remarkable anti-tumor 
activity in both melanoma cell lines and xenograft models expressing EDNRB 
(Asundi et al., 2011). Further studies assessed the combinatorial effect of anti-
EDNRB ADC with MAPK inhibitors. The exposure to MAPK inhibitors to cell lines 
and tumor models harboring either wild type or mutant BRAF and NRAS promoted 
expression of EDNRB, even in cells resistant to MAPK inhibitors. The increased 
expression of EDNRB in turn enhanced the anti-tumor activity of the ADC. Taken 
together, these data indicate that the combination of MAPK inhibitors with anti-
EDNRB ADC might be a powerful and effective approach in a broad range of 
patients with melanoma (Asundi et al., 2014).    
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A more recent study explored the role of endothelin during resistance to BRAFi. 
Treatment with BRAFi increases MITF expression in melanoma cells, which is 
heterogeneously maintained among tumors cells. When MITFhigh and MITFlow 
melanoma cells were co-cultured in the presence of BRAFi, MITFhigh protected 
MITFlow melanoma cells and stimulated their growth. The shielding effect was 
maintained by EDN1 released from BRAFi resistant cells which protected 
otherwise drug-sensitive melanoma cells and led to ERK re-activation via PCK and 
CRAF pathways activation. Endothelin signaling also perturbates AXLhigh 
melanoma cells since monotherapy with BRAFi increased AXL levels and 
combination with endothelin blockage reduced AXL expression. These findings 
suggest the endothelin signaling is an important regulator of melanoma resistance 
to BRAFi (Smith et al., 2017).  
Furthermore, endothelin coordinates the phenotypic heterogeneity that takes 
place when tumors become resistant to BRAFi. The phenotypic heterogeneity is 
demonstrated by the correlation between endothelin receptors and MITF/AXL 
expression levels. Melanoma cells with MITFhigh phenotype have an increased 
expression of EDNRB but reduced levels of EDNRA; in AXLhigh tumor cells this 
correlation is inverted. Therefore, BRAFi treatment increases MITF expression 
which in turn leads to EDN1 production. Endothelin 1 might have an autocrine 
effect and binds to EDNRB in MITFhigh cells (or paracrine in other MITFhigh cells) 
re-activating ERK and consequently regulating proliferation and survival. 
Endothelin 1 might also act in a paracrine fashion in AXLhigh cells upregulating 
EDNRA. In the paracrine context, endothelin signaling re-activates ERK but 
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promotes only cell proliferation. In addition to interfering with the activation of 
BRAF, combination of BRAFi with endothelin receptor blockage might also act in 
the TME as endothelin in crucial for many stromal cells (Smith et al., 2017). 
1.4. Research Questions 
Melanoma is one of the most immunogenic types of tumors and is also known 
to grow in an immunosuppressive environment. The latter affords tumorigenic cells 
with the ability to escape the immune system and ultimately progress and 
metastasize. The Edn3/Ednrb pathway is considered a marker for melanoma 
progression. Still, it is not clear whether melanoma cells themselves or other cells 
present in the TME respond to endothelin signaling. Despite its many 
demonstrated pro-tumorigenic functions, it is still uncertain if endothelin is 
important for immune escape. Regulatory T cells are strong immunosuppressive 
cells present in the TME that limit tumor-specific immune responses and promote 
immune evasion as well as cancer progression. Currently there is no information 
about Treg cells responding to endothelin signaling in melanoma. My central 
hypothesis is that overexpression of Edn3 creates an immunosuppressive 
environment promoting melanoma growth and progression. To test the 
hypothesis, I will address the following questions: 
Question 1: Does End3/Ednrb signaling promote melanoma progression? 
I evaluated the role of Edn3 signaling in melanoma progression by injecting 
relevant murine melanoma cell lines in an immunocompetent mouse model that 
overexpresses Edn3 in the skin (K5-tTA;TRE-Edn3-lacZ which will be referred to 
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as K5-Edn3). I found that when Edn3 is overexpressed in the TME, tumors grow 
significantly more and are more aggressive. 
Question 2: Can tumorigenic and stromal cells respond to Edn3 in the 
microenvironment?  
To address this question I characterized Ednrb expression in different 
population of immune cells present in the melanoma TME. I observed that Treg is 
the only population in TME that has consistently different amounts when Edn3 is 
overexpressed.    
Question 3: Does End3/Ednrb signaling play immunosuppressive roles in the 
melanoma TME? 
I addressed the inhibitory effect of endothelin signaling during the immune 
response against melanoma. I found that Endothelin was required for immune 
escape of highly immunogenic melanoma cells. The immunosuppressive features 
of Tregs were enhanced in presence of Edn3. Overexpression of Edn3 in the 
melanoma microenvironment resulted in upregulation of immunosuppressive 
cytokines and decreased levels of cytokines that elicit anti-tumor immunity. 
Melanomas exposed to high levels of Edn3 were sensitive to immune checkpoint 
inhibitor as well as to Ednrb blockage.  
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1.5. Figures 
 
 
Figure 1.1 Melanoma progression pathways 
The linear pathway of progression from melanocytes to non-CSD or CSD metastatic 
melanomas involves the development of intermediate lesions through the acquirement 
of a series of genetic alterations. Alternatively, during the parallel pathway the 
development of melanocytic lesions may not require some precursor lesions to form 
metastatic melanoma. 
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Figure 1.2 Cells types and signaling molecules in the tumor microenvironment 
(TME) 
The different cell populations present in the tumor microenvironment and their 
relationship is represented here. Cells from the tumor immune surveillance system can 
detect nascent cancer cells and eliminate them. Immune suppressive cells impair the 
mechanisms of immune surveillance which favor tumor progression. CAFs, endothelial 
cells and other signaling molecules also support the tumor development.      
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Figure 1.3 Macrophage polarization 
Monocytes can be polarized towards M1 or M2 type of macrophages. The cytokine IFN-
γ polarizes monocytes towards M1 phenotype, which produces IL-1, IL-6, IL-12 and 
TNF-α cytokines. M2 macrophages are induced by IL-10, TGF-β, IL-4 and IL-13 
cytokines and produce anti-inflammatory cytokines.   
 
  
52 
 
 
Figure 1.4 Naïve CD4+ T cell differentiation 
Naïve CD4+ T cell differentiates into different effector subtypes depending on which 
cytokines are available during antigen presentation by APCs. Each subtype has a 
different biological role and is distinguished by its own cytokine profile.   
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Figure 1.5 Tumor inhibitory cytokine network 
A small number of cytokines are responsible for controlling tumor immune surveillance. 
TH1 cells secrete IL-2 (which sustain the proliferation of cytotoxic cells) and IFN-γ, a 
cytokine that polarizes macrophages towards M1 phenotype. M1 macrophages produce 
IL-12 and pro-inflammatory cytokines IL-1, IL-6 and TNF-α that regulate anti-tumor 
immunity. 
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Figure 1.6 Cellular targets of immunosuppressive cytokines 
IL-10 and TGF-β are central modulators of immunosuppression in the TME. These 
cytokines inhibit the anti-tumor activity of NK cells, TH1, CTL, DC and M1 cells  and 
activate Treg cells.    
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Figure 1.7 Endothelin and inflammation 
Endothelin regulates important events that happen during inflammation. Endothelin 
increases vascular permeability and the expression of adhesion molecules in blood 
vessels. Endothelin also recruits leukocytes and stimulates the secretion of pro-
inflammatory cytokines. Endothelial cells, macrophages, DCs and monocytes are some 
of the cell populations that supply the inflammatory milieu with endothelin. 
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Figure 1.8 Endothelin signaling activation in melanoma cells 
The activation of Edn3/Ednrb axis in melanoma cells triggers many cellular mechanisms 
that promote melanoma progression. 
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2.1. Introduction 
Expression of endothelins and their cognate receptors have been detected in 
a variety of tumor types (Nelson et al., 2003). Colon (Egidy, Juillerat-Jeanneret, et 
al., 2000), lung (Giaid et al., 1990), bladder (Said et al., 2011), prostate (Gohji et 
al., 2001) ovarian (Rosanò, Spinella and Bagnato, 2010) and breast (Grimshaw, 
2005) cancers are examples of carcinomas that express components of the 
endothelin signaling pathway. Glioblastoma (Egidy, Eberl, et al., 2000) and 
melanoma (Demunter et al., 2001) are non-carcinomas that also express 
endothelin. As previously discussed in Chapter 1, it has been clearly demonstrated 
that tumor cells express endothelin. It is has also become evident that endothelin 
is not only expressed by tumor cells but also by  multiple populations of stromal 
cells in the TME including fibroblasts, endothelial and immune cells (Rosanò, 
Spinella and Bagnato, 2013; Rosanò and Bagnato, 2016). It is also widely 
accepted that stromal cells in the TME are major players during tumor 
development. Based on these findings endothelin has been proposed as an 
important modulator of tumor-stromal cells interactions in the TME (Binder et al., 
2009).   
Very interestingly, the expression pattern of endothelins and their cognate 
receptors in the TME is different when epithelial and non-epithelial tumors are 
compared. In carcinomas, the main source of endothelin ligands in the TME is 
usually the tumor cells themselves. With respect to the receptors, there is some 
variability in that Ednra is mostly expressed by cancer cells such as in prostate, 
ovarian and breast cancer whereas the expression of Ednra is generally detected 
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in other cells inside the TME such as in glioblastoma (Aubert and Juillerat-
Jeanneret, 2016). 
The non-carcinoma type of cancer for which the endothelin pathway has been 
best characterized is glioblastoma. In glioblastoma, stromal cells express Ednra 
and are the main source of endothelin while tumors cells express Ednrb (Egidy, 
Eberl, et al., 2000). Although melanoma is considered a non-carcinoma type of 
tumor, it may also share some features with carcinomas because melanocytes 
originate from ectodermal-derived neural crest cells (Braeuer et al., 2014). 
Melanoma cells express EDNRB (Yohn et al., 1994; Lahav, Heffner and Patterson, 
1999; Bagnato et al., 2004; Asundi et al., 2011) as well as secrete EDN1 (Chiriboga 
et al., 2016) and EDN3 (Tang et al., 2008).It is not clear whether stromal cells 
respond to the endothelin  available in the melanoma microenvironment. Recently, 
Chiriboga and colleagues detected the expression of EDN1 in macrophages found 
in melanoma tumors. Yet, the authors did not address the expression of endothelin 
receptors in stromal cells (Chiriboga et al., 2016). 
Regardless of the embryonic origin of cancer cells, endothelin signaling plays 
diverse roles in the TME (Figure 2.1). In the TME, the endothelin pathway has 
been mostly evaluated in fibroblasts and endothelial cells. Endothelin participates 
in a bidirectional stimulatory loop involving breast cancer cells and fibroblasts in 
the TME. Tumor cells secrete EDN1 that stimulates the production of inflammatory 
mediator PGE2 in fibroblasts. In presence of pro-inflammatory cytokine IL-1, PGE2 
induces EDN1 production in tumor cells (Patel, Sheth and Schrey, 1997). 
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Endothelin signaling mediates the conversion of quiescent fibroblasts into cancer-
associated fibroblasts (CAFs) in colon cancer, which is crucial for the creation of 
the permissive stroma for tumor cells. In vitro activation of each endothelin receptor 
produces different outcomes in CAFs and blockage of endothelin receptors 
prevents CAFs activity. Activation of EDNRA promotes cell growth while EDNRB 
stimulation is responsible for CAFs migration. Both EDNRA and EDNRB regulates 
CAFs contraction. Additionally, EDN1 induces the expression of profibrotic genes, 
secretion of ECM components and MMP-2 (Knowles et al., 2012).  
The connection between endothelin and endothelial cells in the TME has been 
addressed in many studies. Endothelin directly and indirectly promotes 
angiogenesis in the TME. EDNRB activation by EDN1 promotes endothelial cell 
proliferation, migration, and invasion (Salani, Taraboletti, et al., 2000). Biding of 
EDN1 on EDNRA expressed by tumor cells results in the secretion of VEGF, the 
master regulator of angiogenesis (Salani, Castro, et al., 2000). Activation of 
endothelin signaling in blood vessels functions as an important regulator of 
immune cell recruitment to the TME. In fact, EDNRA and EDNRB show contrasting 
effects in the recruitment of tumor-specific lymphocytes. Overexpression of 
EDNRB in endothelial cells from aggressive glioblastomas and ovarian cancer is 
associated with less cytotoxic T lymphocytes (CTLs) infiltration (Buckanovich et 
al., 2008) and more regulatory T cells (Tregs) present in the TME. These data 
suggest that high expression of EDNRB in TME cells impairs recruitment of tumor 
inhibitory immune cells while contributing to evasion of immune detection 
(Nakashima et al., 2016). EDNRB blockage increases the expression of adhesion 
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molecules ICAM-1 in the vasculature, which in turn enhances lymphocytes homing 
to the TME (Buckanovich et al., 2008). Ovarian tumors treated with dual 
EDNRA/EDNRB inhibitor showed an unexpected decrease in ICAM-1 expression 
and consequently a reduced amount of CD8+ infiltrate. This finding implicates that 
EDNRA activation is essential for anti-tumor cells recruitment while stimulation of 
EDNRB prevents CTL mediated responses against tumors (Coffman et al., 2013). 
Accordingly, EDNRB blockage alone might be more beneficial to patients than 
simultaneous inhibition of EDNRA and EDNRB.  
Endothelin is considered a chemoattractant for macrophages to the TME. 
EDN1 produced by bladder cancer cells promotes macrophage recruitment via 
chemokine CCL2 production (Said et al., 2011). Beyond chemotaxis, endothelin 
also increases the expression of genes associated with macrophage activation 
(Grimshaw, Wilson and Balkwill, 2002). Tumor-derived EDN1 stimulates EDNRA 
activation in tumor-associated macrophages (TAMs) resulting in production of pro-
inflammatory cytokines TNF-α, IL-6 and COX-2 (Said et al., 2011).TAMs also 
induce activation of endothelin signaling in endothelial and breast cancer cells. 
This activation promotes the expression of adhesion molecules resulting in cancer-
endothelial cell adhesion and transendothelial migration (Chen et al., 2014). 
Dendritic cell (DC) is another type of antigen presenting cell (APC) of which 
function is regulated by endothelin signaling. Remarkably, each endothelin 
receptor impacts DCs function in opposite manners. EDNRA expression in human 
DCs increases the expression of activation markers, enhancing DCs capability to 
activate T cells. EDNRA consequently mediates antigen presentation features of 
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DCs. DCs expressing EDNRA secrete immunomodulatory cytokine IL-12 and 
show reduced apoptosis. In contrast, expression of EDNRB by DCs decreases 
their maturation and survival suggesting that EDNRB suppresses immune 
response (Guruli et al., 2004).  
Several studies using tumor types other than melanoma have explored the 
microenvironmental role of endothelin signaling. Edn3/Ednrb is considered a 
marker for melanoma progression. EDN3 (Tang et al., 2008) as well as EDNRB 
(Demunter et al., 2001) expression has been detected in melanoma patients. Still, 
the exact cellular type expressing the receptor in the TME has not been 
determined. The present study investigated the microenvironmental expression of 
Ednrb in mouse and human melanomas. 
2.2. Results  
To better understand the role of endothelin signaling in the melanoma 
microenvironment green fluorescent protein (GFP) labeled YUMM1.7 and B16F10 
murine melanoma cells were subcutaneously and intradermally injected in wild-
type and K5-tTA; TRE-Edn3-lacZ (K5-Edn3, for simplicity) transgenic mice. The 
K5-Edn3 mouse model was developed in our laboratory and overexpresses Edn3 
in the skin. In this system, the overexpression of Edn3 is under the control of the 
keratin 5 promoter. Due to the abundance of Edn3 in the skin, melanocytes are 
maintained in the dermal/epidermal junction, mimicking their location in human 
skin (Garcia et al., 2008). The aberrant expression of Edn3 in the skin of K5-Edn3 
mice is shown in Figure 2.2A. 
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Human melanoma initiation and development are mainly driven by activation 
of oncogenic protein BRAFV600E as well as deletion of PTEN and CDKN2A genes 
(Shain and Bastian, 2016). These genetic alterations have recently been modeled 
in the YUMM1.7 mouse cell line (Meeth et al., 2016). YUMM1.7 cells were derived 
from BRafV600E/+;Pten-/-; Cdkn2a-/- transgenic mice (Scortegagna et al., 2014). 
Consequently, these cells carry mutations commonly found in human melanomas. 
Since YUMM1.7 cells are not pigmented they were labeled with GFP to facilitate 
the detection of metastatic cells. Figure 2.2B illustrates the protocol used to 
generate the YUMM1.7-GFP melanoma cells. B16F10 melanoma cells were 
derived from a spontaneous murine tumor in the early 1970’s (Fidler, 1973) and 
are still extensively employed in cancer research due to its highly aggressive 
features. B16F10-GFP cells were injected in both K5-Edn3 and wild-type mice to 
test the environmental role of Edn3 in a widely used melanoma model.  
 Endothelin increases tumor aggressiveness 
YUMM1.7-GFP melanoma cells generated detectable tumors 7 days after 
subcutaneous injection. Both wild-type and K5-Edn3 tumors had similar growth 
rates during the following 7 days. Seventeen days after injection the subcutaneous 
tumors in K5-Edn3 mice started to grow faster than wild-type. K5-Edn3 and wild 
type tumors had an average volume of 1054 mm3 and 673 mm3, respectively. K5-
Edn3 tumors continued to grow faster for the next days. Twenty-one days after 
injection K5-Edn3 tumors were significantly larger (p<0.05) than wild-type tumors 
(Figure 2.3A). Once tumors reached a volume close to 2 cm3 the mice were 
euthanized. Autopsy did not reveal any visible metastasis although cross-
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sectioning of lungs showed the presence of GFP+ cells in the lungs of one K5-
Edn3 mouse (Figure 2.3B). Since Edn3 overexpression in the K5-Edn3 mice is 
restricted to the skin, YUMM1.7-GFP cells were intradermally injected in the mice 
to ensure that melanoma cells were exposed to an Edn3-rich environment. 
Intradermal injection of YUMM1.7-GFP cells showed similar results to those 
observed upon subcutaneous injection. Intradermal YUMM1.7-GFP tumors 
generated in K5-Edn3 mice were approximately two times larger than in wild-type 
mice (p<0.05) (Figure 2.4A) and lung metastases (n=1) was detected only when 
the primary tumors were exposed to abundant Edn3 (Figure 2.4B).  
In order to validate the observations made using YUMM1.7-GFP cells, B16F10-
GFP melanoma cells were injected in both wild-type and K5-Edn3 mice. Similar to 
YUMM1.7-GFP, intradermal B16F10-GFP tumors were more aggressive when 
growing in presence of Edn3. Tumors generated in K5-Edn3 mice were six times 
larger than in wild-type mice (p<0.05) (Figure 2.5A) and only K5-Edn3 tumor (n=1) 
metastasized to the lungs (Figure 2.5B). These results indicate that Edn3 is 
responsible for melanoma growth and corroborates previous reports claiming that 
endothelin is considered a marker for melanoma progression. 
 Melanoma cells express Ednrb  
Given the effect of overexpression of Edn3 on YUMM1.7-GFP tumors, I asked 
whether tumor cells express Ednrb and therefore are capable to respond to Edn3 
present in the microenvironment. EDNRB expression has already been 
demonstrated in human melanoma cell lines. Immunofluorescence staining for 
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GFP and Ednrb detected GFP+ melanoma cells expressing Ednrb in both wild-type 
and K5-Edn3 tumors (Figure 2.6A, white arrows). The antibody against GFP was 
used in order to amplify the signal for immunostaining. The visual inspection of four 
sections per tumor from YUMM1.7-GFP tumors (n=5/group) showed that very few 
melanoma cells expressed Ednrb.  
In an effort to quantify Ednrb+/GFP+ melanoma cells, tumors were dissociated 
and analyzed using flow cytometry. A small population of GFP+ melanoma cells 
that expressed Ednrb was found in both groups (Figure 2.6B). There was no 
significant difference (p>0.05) between the amount of Ednrb+/GFP+ melanoma 
cells in wild-type and experimental tumors (Figure 2.6C). Immunostaining showed 
that a large number of GFP- cells were positive for Ednrb (Figure 2.6A). 
Additionally, flow cytometry plots revealed a large and well-defined population of 
GFP-/Ednrb+ cells (Figure 2.6B). These observations suggest that Ednrb is 
expressed in stromal cells.   
 Ednrb expression in the melanoma microenvironment 
To further characterize the populations of non-tumorigenic cells present in the 
TME, tumors were stained with different markers of stromal cells and analyzed 
using flow cytometry. Fibroblasts were detected using CD140a (PDGF-R) marker 
(Betsholtz, Karlsson and Lindahl, 2001), endothelial cells were labeled with CD146 
antibody (Bardin et al., 2001) and leukocytes were identified using the pan-
leukocyte marker CD45 (Trowbridge and Thomas, 1994). The presence of immune 
cells from the myeloid lineage (Misharin et al., 2013) were assessed using the 
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following markers: F4.80 for macrophages (Austyn and Gordon, 1981), Ly6G for 
neutrophils (Daley et al., 2007) and CD11c for DCs (Osugi, Vuckovic and Hart, 
2002). Lastly, cells from the lymphoid lineage, namely natural killer (NK) cells, 
CTLs, and Tregs were detected using NK1.1 (Stenström et al., 2005), CD8a 
(Bierer et al., 1989) and CD25 (IL-2Rα) (Lee, 2017) markers, respectively.  
All markers used stained positively demonstrating that the YUMM1.7-GFP 
melanoma microenvironment is very complex and comprised of a mixture of 
stromal cells (Figure 2.7). Overall, the number of non-malignant cells in tumors 
resulting from subcutaneous injections in wild-type and K5-Edn3 tumors was not 
significantly different (p>0.05). The same pattern was observed in intradermal 
tumors (p>0.05) (Figure 2.7). One crucial exception was observed for Tregs. In 
both subcutaneous and intradermal injection-generated melanomas there were 
approximately two times more Tregs in K5-Edn3 tumors when compared to wild-
type tumors (p<0.01) (Figure 2.7C). This finding indicates that when Edn3 is 
present in the melanoma microenvironment there is an enrichment of intratumoral 
Tregs.  
Immunofluorescence staining for Ednrb and the pan-leukocytes marker CD45 
revealed that in both wild-type and experimental tumors there were several 
immune cells that expressed Ednrb (Figure 2.8). To further characterize the 
immune cell populations that expressed Ednrb, tumors were again dissociated and 
stained for flow cytometry analysis using different markers for stromal cells and co-
stained with Ednrb antibody. All assessed stromal cells expressed Ednrb (Figure 
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2.9) but the exact populations of cells varied depending on the tumor location. 
Subcutaneous tumors in K5-Edn3 mice exhibited more Ednrb+ endothelial cells 
(Figure 2.9A) and CTLs (Figure 2.9C) than wild-type tumors (p<0.05), a pattern 
not replicated in intradermal tumors (p>0.05). On the other hand, intradermal 
tumors in K5-End3 mice showed more DCs  (Figure 2.9B) that expressed Ednrb 
(p<0.05), a trend not observed in subcutaneous tumors (p>0.05). Treg was the 
only population that consistently expressed high levels of Ednrb in both 
subcutaneous and intradermal tumors in K5-End3 mice (p<0.05) (Figure 2.9C). 
This result corroborates the previous finding that the endothelin axis affects 
intratumoral Tregs.  
 Ednrb expression in human melanoma 
Lastly, I investigated whether the findings from YUMM1.7-GFP melanoma 
mouse model are relevant for melanoma patients. Publicly available RNA-seq data 
of melanoma samples from 19 patients (Tirosh et al., 2016) showed that EDNRB 
is expressed by melanoma cells and several populations of stromal cells in the 
TME (Figure 2.10A). In contrast to YUMM1.7-GFP tumors, malignant cells in the 
human melanoma TME highly expressed EDNRB. As noticed in the YUMM1.7-
GFP tumors, fibroblasts, endothelial cells, macrophages, T, and NK cells 
expressed different levels of EDNRB. T cells exhibited the highest level of EDNRB 
expression in melanoma microenvironment. Next, the expression of EDNRB in 
intratumoral Tregs was assessed. Tregs were defined as the subpopulation of T 
cells expressing CD25 or FOXP3. There were few intratumoral Tregs that 
expressed EDNRB in melanoma tumors (Figure 2.10B). These data are in 
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accordance with the findings in the YUMM1.7-GFP tumors and suggest that 
endothelin signaling is important for stromal cells in the melanoma 
microenvironment, particularly Tregs. 
2.3. Discussion  
Notwithstanding initial controversy (Kikuchi et al., 1996), Ednrb has long been 
demonstrated to be overexpressed in aggressive melanomas. Indeed, Edn3/Ednrb 
signaling is currently considered a marker for melanoma progression (Demunter 
et al., 2001). The present study strengthens these earlier findings showing that 
overexpression of Edn3 in the melanoma microenvironment increases tumor 
aggressiveness. Larger and metastatic melanoma were developed when primary 
tumors were exposed to a microenvironment rich in Edn3. Similar results were 
observed using YUMM1.7 cell line, which harbor BrafV600E (Meeth et al., 2016), and 
B16F10, a melanoma cell line considered Braf wild-type (Melnikova et al., 2004; 
Hooijkaas et al., 2012). Oncogenic BRAFV600E is found in about 50% of human 
melanomas (TCGA, 2015). Findings from the present study suggest that 
endothelin signaling is relevant to a broad range of melanomas, including 
BRAFV600E and BRAF wild-type. It should be noted that endothelin might be crucial 
for BRAFV600E mutated melanomas. Recent reports have shown that melanoma 
treated with BRAFi tend to have increased expression of both Ednrb and Edn1 
(Asundi et al., 2014; Smith et al., 2017). Thus, combinatory treatments targeting 
endothelin signaling and oncogenic BRAF might be an effective therapeutic 
approach for a particular subset of melanoma patients.   
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Despite the canonical role of Edn3/Ednrb axis during melanoma progression, 
to this date it is not clear the cellular distribution of endothelin signaling 
components in the melanoma microenvironment. In vitro and in vivo expression of 
EDN1 (Chiriboga et al., 2016) as well as EDN3 (Tang et al., 2008) have been 
described in human melanoma cells. Recently, an in vitro study showed that EDN1 
mediates the communication between endothelial and melanoma cells and 
enhances their vasculogenic ability (Spinella et al., 2014). Expression of EDN1 
was also detected in intratumoral macrophages from melanoma biopsies 
(Chiriboga et al., 2016). EDNRB expression in melanoma has been mostly 
described in melanoma cell lines (Yohn et al., 1994; Lahav, Heffner and Patterson, 
1999; Bagnato et al., 2004; Asundi et al., 2011). Although EDNRB expression is 
reported in patients with melanoma (Bittner et al., 2000; Demunter et al., 2001), 
the precise cellular type expressing the receptor in the TME had not been 
addressed. In this respect, Ednrb expression was detected in GFP+ melanomas 
cells from YUMM1.7-GFP tumors. However, no difference in the amount of 
GFP+/Ednrb+ was found when K5-Edn3 and wild-type tumors were compared. Yet, 
in both control and experimental YUMM1.7-GFP tumors the expression of Ednrb 
was detected in a small percentage of melanoma cells. Many non-malignant cells 
expressed Ednrb in YUMM1.7-GFP tumors, suggesting a possible environmental 
role of endothelin signaling in the melanoma microenvironment. Thus, stromal 
activation of endothelin signaling might be central to the aggressive phenotype of 
K5-Edn3 tumors. In breast cancer, the role of stromal Ednrb has been explored in 
detail. Injection of breast cancer cells overexpressing Ednra generated tumors with 
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diminished growth and metastatic potential in Ednrb deficient rat. Lack of stromal 
Ednrb did not affect angiogenesis but considerably impaired the infiltration of 
immune cells and cytokine production resulting in reduced tumor aggressiveness. 
The absence of Ednrb in the TME decreased the recruitment of TAMs and the 
amount of pro-inflammatory cytokine TNF-α. In contrast, the amounts of T 
lymphocytes and NK cells, as well as IL-10 cytokine were not affected by the 
deficiency of Ednrb in the TME (Binder et al., 2009). 
Melanoma microenvironment is comprised of several cell types. Tirosh and 
colleagues elegantly described different populations of stromal cells existing in 
human metastatic melanoma microenvironment. CAFs and endothelial cells 
together with NK and macrophages represent a small percentage of melanoma 
stroma. The majority of melanoma stroma consists of B lymphocytes and T cell 
subtypes including CD8, CD4, and Treg (Tirosh et al., 2016). Basic 
characterization of YUMM1.7 tumors revealed that these melanomas have 
considerable immune infiltrate. As opposed to human melanomas the majority of 
immune infiltrate was comprised of macrophages. Lymphocytes represented less 
than 1% of immune cells in the microenvironment (Meeth et al., 2016). A more 
sophisticated portrayal of the melanoma immune infiltrated from a different 
BrafV600E mutated mouse melanoma cell line (BPD6) showed the presence CTLs, 
DCs, TAMs and myeloid-derived suppressor cells (MDSCs) in the TME (Liu et al., 
2018).   
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The above-mentioned findings were confirmed in this study by demonstrating 
that YUMM1.7-GFP melanoma microenvironment is comprised of CAFs, 
endothelial cells and a variety of leukocytes including macrophages, neutrophils, 
DCs, NK, CTLs and Tregs. The higher amount of T cells in YUMM1.7-GFP tumors 
compared to the original YUMM1.7 cells might be explained by differences in the 
genetic background of mice used in the present study. In order to make the 
YUMM1.7 cells syngeneic (that is, genetically identical) to C57BL/6 mice, the 
YUMM1.7 cells were generated in transgenic mice after a series of backcrosses 
with C57BL/6 mice (Meeth et al., 2016). In contrast, the K5-Edn3 transgenic mice 
and their wild-type counterparts were generated using mice from C57BL/6 and 
FVB/N genetic backgrounds (Garcia et al., 2008). Therefore, the YUMM1.7-GFP 
cells might not be syngeneic to the K5-Edn3 mice. Upon injection in 
immunocompetent K5-Edn3 mice, YUMM1.7-GFP cells might have induced a 
strong immune response, which may explain the discrepancy in the T cell infiltrates 
of YUMM1.7 and YUMM1.7-GFP tumors. Another reason could be the fact that 
YUMM1.7-GFP cells were GFP labeled using lentivirus. GFP is a protein originated 
from jellyfish that can induce immune responses in immunocompetent mice (Day 
et al., 2014), a reaction also triggered by viral particles of lentivirus vector (Nayak 
and Herzog, 2010).  
The present study showed for the first time that Ednrb is expressed in several 
cell populations within melanoma microenvironment. The microenvironmental role 
of endothelin signaling has been explored in many tumor types other than 
melanoma. Endothelin derived from colorectal cancer cells acts in a paracrine 
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fashion on endothelin receptors exhibited by fibroblast and stimulates its growth, 
migration, and contraction. Blockage of both EDNRA and EDNRB efficiently 
inhibited the EDN1 induced effects in colonic fibroblasts (Haque et al., 2013). In 
response to EDN1, CAFs reduce the expression of genes associated with 
inflammation, namely IL-8 and SMAD5 (Knowles et al., 2012). This suggests that, 
although considered a pro-inflammatory cytokine (Nett et al., 2006), in some 
contexts endothelin might negatively regulate the inflammatory milieu in the TME.  
Stromal endothelin is classically associated with angiogenesis. Indeed, high 
expression of EDN1 is correlated with neovascularization in ovarian cancer 
(Salani, Castro, et al., 2000). A mechanism employed by mesenchymal stem cells 
(MSC) that contributes to endothelin-induced angiogenesis in the TME has 
recently been described. MSCs produce IL-6, which controls the secretion of EDN1 
by colorectal cancer cells. Endothelin promotes ERK and Akt phosphorylation in 
endothelial cells, thus increasing endothelial cells recruitment and formation of new 
blood vessels (Huang et al., 2013). Transcriptional profile of endothelial cells from 
ovarian cancer revealed that more aggressive tumors have less tumor infiltrates 
lymphocytes (TIL) because of EDNRB overexpression. EDNRB decreases the 
expression of adhesion molecule ICAM-1 and consequently prevents recruitment 
of CTLs to the TME. Endothelin attenuates lymphocyte clustering to endothelial 
cells even in the presence of pro-inflammatory cytokine TNF-α. Therefore, EDNRB 
activation in endothelial cells present in the TME creates an endothelial barrier 
sustaining the immune-privileged microenvironment. Preclinical studies showed 
that EDNRB blockage enhances otherwise ineffective immunotherapy strategies 
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increasing CD8+ homing to the TME. Targeting EDNRB also promotes activation 
of anti-tumor lymphocytes as shown by the upregulation of IFN-γ and IL-2 
cytokines (Buckanovich et al., 2008). Thus, EDNRB activation in the TME 
suppresses T cell recruitment facilitating immune escape and EDNRB antagonists 
can be used in combination with immunotherapy to improve anti-tumor immune 
response (Kandalaft et al., 2009, 2011). EDNRA seems to increase ICAM-1 
expression on endothelial cells enhancing the recruitment of tumor inhibitory 
immune cells (Coffman et al., 2013). Hence, EDNRA activation in the TME is 
important for anti-tumor response while EDNRB stimulation prevents immune 
response against tumor cells (Aubert and Juillerat-Jeanneret, 2016). This data is 
to a certain extent conflicting with the observation that subcutaneous tumors in K5-
Edn3 mice had great quantities of endothelial cells that express Ednrb while 
exhibiting more Ednrb+ CTL. The fact that K5-Edn3 tumors were larger and 
metastatic suggests that the effect of Ednrb in subcutaneous YUMM1.7-GFP 
tumors is not restricted to the recruitment of CTLs. This effect might be related to 
other stromal population such as Tregs, which can further inhibit tumor-specific 
CTLs.   
Endothelin signaling is an important regulator of DCs function and survival. 
Activation of immature DCs with TNF-α induce human DCs to secrete endothelin 
and to express endothelin receptors. EDNRA stimulation enhances antigen 
presentation by DCs as well as production of IL-12, a major regulator of TH1 
polarization. On the other hand, activation of EDNRB prevents DCs activation. 
These data suggest that endothelin might have an autocrine effect on DCs and the 
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balance of endothelin receptors is involved in the generation of TH1 response 
(Guruli et al., 2004). The negative regulatory effect of Ednrb in anti-tumorigenic 
cells such as DCs might explain the fact that K5-Edn3 tumors are more aggressive 
even though they had a higher number of Ednrb+ DCs.  
The present study supports the hypothesis that endothelin signaling may have 
multiple effects in melanoma microenvironment given that different populations of 
stromal cells expressed Ednrb in the YUMM1.7-GFP tumors. Importantly, this is 
the first report of Ednrb expression in NK cells and Tregs in TME. In both control 
and experimental YUMM1.7-GFP melanomas, Ednrb expression was detected in 
anti-tumor cells including CTLs, NK and DCs as well as pro-tumorigenic cells, 
namely CAFs, TAMs, and Tregs. The fact that Ednrb expression is detected in 
both anti- and pro-tumorigenic cells suggests potential opposite functions of 
endothelin signaling in the melanoma microenvironment. Thus, the balance of 
endothelin signaling activation among stromal cells that antagonize or promote 
tumor development determines the fate of melanoma progression. Given that K5-
Edn3 tumors have a more aggressive phenotype, it is reasonable to assert that in 
Edn3-rich microenvironment the net result favors the effect of endothelin in pro-
tumorigenic cells.  
Treg is the only population that is numerically different when K5-Edn3 tumors 
are compared to wild-type tumors. Therefore, it is tempting to claim that Tregs are 
responsible for creating an immunosuppressive environment inside melanoma 
tumors, allowing for the escape from immunosurveillance. Aggressive 
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glioblastomas express high levels of EDNRB and show reduced infiltration of CTL 
along with increased number of Tregs. This data supports the notion that activation 
of stromal EDNRB suppresses host anti-tumor immunity (Nakashima et al., 2016). 
It is not clear whether the augmented amount of intratumoral Ednrb+ Tregs in the 
K5-Edn3 tumors is a consequence of increased Treg recruitment, proliferation or 
differentiation from conventional T cells. Finally, EDNRB+ Tregs were detected in 
the human metastatic melanoma microenvironment suggesting that Tregs might 
respond to EDN1 and EDN3 present in human melanomas and orchestrate 
immunosuppression accountable for melanoma aggressiveness. Together, the 
results presented here support the use of EDNRB blockage in combination with 
immunotherapy  (Buckanovich et al., 2008) as a therapeutic approach to be 
considered for patients with aggressive melanomas.   
2.4. Methods 
 Mice and genotyping 
The K5-tTA; TRE-Edn3-lacZ (K5-Edn3, for simplicity) transgenic mice were 
generated in our laboratory (Garcia et al., 2008). K5-Edn3 mice constitutively 
overexpress Edn3 in the skin using a tetracycline-inducible system. Transgenic 
expression of Edn3 is driven by the tTA activator in the regulatory region of the 
Bos taurus gene for Keratin 5. Mice from K5-tTA; TRE-Edn3-lacZ intercrosses that 
harbored either K5-tTA or TRE-Edn3-lacZ transgene were denominated wild-type 
due the lack of transgenic overexpression of Edn3. A small piece of mouse tail was 
used as a DNA source for genotyping. After DNA extraction PCR was carried out 
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using the following primers: 5’-CCAGGTGGAGTCACAGGATT-3’ and 5’-
ACAGAGACTGTGGACCACCC-3’ for K5-tTA transgene and 5’-
AGGCCTGTGCACACTTCTGT-3’ and 5’-TCCTTGTGAAACTGGAGCCT-3’ for 
the TRE-Edn3-lacZ transgene. All animals were housed in the University Animal 
Care Facility at Florida International University. The study was approved by the 
Institutional Animal Care and Use Committee (IACUC) at Florida International 
University protocol number 16-018.  
 Cell lines  
YUMM1.7, a gift from Dr. Marcus Bosenberg (Yale University), and B16F10 
murine melanoma cell (ATCC) lines were labeled with GFP using recombinant 
lentivirus pHIV-Ednrb-EGFP. The lentivirus transduction procedure was carried 
out at Florida International University Tissue Cell Culture Facility. The generation 
of GFP labeled cells was approved by Institutional Biosafety Committee (IBC) 
protocol number 16-027. YUMM1.7-GFP cells were cultured with DMEM/F-12 
supplemented with 10% fetal bovine serum and penicillin/streptomycin. B16F10-
GFP cells were cultured in supplemented DMEM medium.  
 Tumor cell injection 
A total of 100,000 melanoma cells were injected in the shaved flank of K5-Edn3 
or wild-type mice. For subcutaneous injection cells were resuspended into 100µl 
of PBS and injected under the skin using 25G needle. For intradermal injection 
cells were resuspended into 50µl of PBS and injected under the superficial layer 
of epidermis using 30G needle (Shimizu, 2004). Tumor length and width were 
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measured twice a week using a digital caliper. Tumor volume was calculated using 
the following formula: volume = (length x width x width)/2 (Cintolo et al., 2016). 
Mice were euthanized when tumors reached 2 cm3 of volume. Statistical analysis 
was carried out with Student T-Test and considered to be significantly different at 
p<0.05. 
 Flow Cytometry 
Harvested tumors were minced finely with a scalpel blade and dissociated 
using collagenase/dispase (Roche 10 269 638) for 45min followed by digestion 
with trypsin 0.25% at 37°C for 5min. Cell suspension was filtered using 40µM cell 
strainer and red blood cells were lysed with ACK lysis buffer. Single-cell 
suspension was stained at 4°C for 30min using the following phycoerythrin-
conjugated antibodies: CD140 (0.25µg, Biolegend, 135905), CD146 (0.06µg, 
Biolegend, 134703), CD45 (0.25µg, Biolegend, 103105), F4/80 (1µg, 
eBiosciences, 12-4801-82), Ly6G (0.25µg, Biolegend, 127607), CD11c (0.25µg, 
Biolegend, 117307), NK1.1 (0.25µg, Biolegend, 108707), CD8a (0.25µg, 
Biolegend, 100707) and CD25 (1µg, Biolegend, 102007). Single-cell suspension 
was also stained with unconjugated rabbit Ednrb antibody (1:200, Proteintech, 
20964-1-AP) followed by secondary staining using anti-rabbit PerCP/Cy5.5 
antibody (1µg, Santa Cruz, sc-45109) or anti-rabbit Alexa 647 antibody (1:2000, 
Abcam, ab150075). Fifty thousand events were acquired using Accuri C6 (BD 
Biosciences) flow cytometer. The flow cytometric profile of each sample was 
analyzed using FlowJo (TreeStar) software. Statistical analysis was carried out 
with Student T-Test and considered to be significantly different at p< 0.05.  
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 Histological and Immunofluorescence Analysis 
Tissues were fixed overnight with 4% paraformaldehyde (PFA), sequentially 
incubated for 12h with 10% and 20% sucrose and cryo-embedded in OCT (Fisher 
23-730-571). Cryosections (10µM) were incubated with blocking buffer (10% 
normal serum, 0.3% Triton X-100, 1% BSA in 1x PBS) at room temperature for 1h. 
Next, primary antibodies were diluted in dilution buffer (1% normal serum, 0.3% 
Triton X-100, 1% BSA in 1x PBS) and added to cryosections for incubation at room 
temperature for 1 hour or at 4°C overnight. Primary antibodies used: Edn3 (1:200, 
Proteintech, 10674-1-AP), CD45 (1:200, Biolegend, 103101), Ednrb (1:400, 
Proteintech, 20964-1-AP) and GFP (1:500, Aves Labs, GFP-1020). Antibody 
against GFP was used in order to amplify the signal for immunostaining. Where 
necessary, GFP fluorescence from lentivirus expression was photobleached by 
treatment with 3% H2O2 in methanol and illumination on a fluorescent light box for 
4 hours. After 3 sequential washes with 1xPBS, cryosections were incubated with 
secondary antibody for 1 hour at room temperature. Secondary antibodies used: 
anti-rabbit Alexa 488 (1:200, Invitrogen, A11008), anti-chicken Alexa 488 (1:500, 
Abcam, ab150169), anti-rat Alexa 488 (1:200, Abcam, ab150159), anti-rabbit 
Alexa 594 (1:200, Invitrogen, A11012). Then, slides were mounted with mounting 
medium containing DAPI (Abcam, ab104139). Slides were visualized using Leica 
DMRB fluorescent microscope and digital pictures were captured with a Leica 
DFC450C camera.  
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 Publicly available RNA-seq data of melanoma samples 
Single-cell gene expression data of melanoma samples was obtained from 
GEO repository, access number GSE72056. Cell types were defined according to 
the classification from Tirosh, et al. (2016). Treg cells were defined as the 
subpopulation of T cells that have the expression level of CD25 or FOXP3> = 0.5 
FPKM. 
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2.5. Figures 
 
Figure 2.1 Mechanisms of action of endothelin in the TME 
Endothelin signaling is activated in diverse populations of stromal cells in the TME. 
Activation of endothelin receptors promotes growth and migration of fibroblasts as well 
as production of ECM components and proteases. Ednrb activation on endothelial cells 
stimulates angiogenic events such as proliferation and migration of endothelial cells. 
Endothelin also controls the production of angiogenic factor VEGF. The differential 
expression of endothelin receptors in endothelial cells regulates the expression of 
adhesion molecules that eventually control the recruitment of lymphocytes to the TME. 
The functions of APCs, namely DCs and macrophages, are also under the control of 
endothelin signaling.     
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Figure 2.2 Melanoma cell line and mouse model 
A. Wild-Type mouse and transgenic mouse model K5-Edn3 used for subcutaneous and 
intradermal injection of established YUMM1.7-GFP melanoma cells. B. Schematic 
protocol used to generate YUMM1.7-GFP melanoma cell line as described in (Meeth et 
al., 2016). 
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Figure 2.3 Endothelin overexpression increases aggressiveness of 
subcutaneous YUMM1.7-GFP melanoma tumors 
A. Tumor volume of mice that received subcutaneous (n=8) injections of YUMM1.7-
GFP melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice 
subcutaneously injected with YUMM1.7-GFP cells. *p<0.05 
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Figure 2.4 Endothelin overexpression increases aggressiveness of intradermal 
YUMM1.7-GFP melanoma tumors 
A. Tumor volume of mice that received intradermal (n=13) injections of YUMM1.7-GFP 
melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice 
intradermally injected with YUMM1.7-GFP cells. *p<0.05 
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Figure 2.5 Endothelin overexpression increases aggressiveness of intradermal 
B16F10-GFP melanoma tumors 
A. Tumor volume of mice that received intradermal (n=11) injections of B16F10-GFP 
melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice 
intradermally injected with B16F10-GFP cells. *p<0.05 
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Figure 2.6 Ednrb is expressed in melanoma cells 
A. Representative photomicrographs of immunofluorescence staining of cryosections of 
intradermally injected YUMM1.7-GFP tumors in wild-type and K5-Edn3 mice for GFP and 
Ednrb. White arrow showing double positive cells. B. Flow Cytometry plots of GFP+/Ednrb+ 
melanoma cells of subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and 
K5-Edn3 mice. C. Percent quantification of flow cytometry data (n=3/group). *p<0.05. 
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Figure 2.7 Populations of stromal cells present in the melanoma TME 
Percent quantification of mesenchymal cells (A), myeloid (B) and lymphoid (C) cells in 
subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice 
(n=3/group). **p<0.01.  
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Figure 2.8 Ednrb is expressed by stromal cells in the melanoma TME 
Representative photomicrographs of immunofluorescence staining of cryosections of 
intradermally injected YUMM1.7-GFP tumors in wild-type (A) and K5-Edn3 mice (B) for 
CD45 (green) and Ednrb (red). White arrows showing double positive cells.  
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Figure 2.9 Ednrb is expressed by a variety of cell types in the melanoma TME 
Percent quantification of Ednrb+ mesenchymal cells (A), myeloid (B) and lymphoid (C) 
in subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice 
(n=3/group) *p<0.05, **p<0.01. 
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Figure 2.10  EDNRB is expressed by a variety of cell types within the human 
melanoma TME 
A. Violin plots showing frequency of malignant and stromal cells expressing different 
EDNRB levels from the single-cell RNA sequencing data of melanoma samples from 19 
patients (Tirosh et al., 2016). B. Violin plot of EDNRB expression in Tregs cells. Treg 
cells were defined as the subpopulation of T cells that have the expression level of CD25 
or FOXP3> = 0.5 FPKM. Pre-processed RNA sequencing data were downloaded from 
supplementary material. 
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3.1. Introduction 
The immunoediting concept suggests that the host immune system hampers 
tumor formation while shaping tumor immunogenicity. Immunoediting occurs in a 
stepwise process. During the elimination phase components of tumor 
immunosurveillance system encounter and demolish emerging tumors. Cancer 
cells that resist the forces of immunosurveillance are kept dormant during the 
equilibrium phase. Lastly, in the escape phase tumor cells that became less 
immunogenic form visible tumors. This last stage is empowered by the 
immunosuppressive setting established in the TME (Schreiber, Old and Smyth, 
2011).  
As demonstrated in Chapter 2, the melanoma microenvironment is 
characterized by infiltration of several immune cell populations. The intense 
recruitment of immune cells to melanoma tumors is a consequence of melanoma 
immunogenicity (Passarelli et al., 2017). Even though notably immunogenic, 
melanoma develops diverse mechanisms to evade immune detection. Indeed, 
melanoma is considered a highly immunosuppressive type of tumor (Umansky and 
Sevko, 2012). Inside the TME, suppressive mediators including cytokines and cells 
create an immunosuppressive network enabling tumors to escape from immune 
detection and destruction by engaging components of the immunosurveillance 
system (Liu, Workman and Vignali, 2016). Intratumoral regulatory T cells (Tregs) 
play a central role in contributing to the formation of the immunosuppressive milieu. 
Therefore, they support tumor development suppressing tumor-specific immune 
responses in the TME (Chaudhary and Elkord, 2016). 
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Tregs have strong immunosuppressive abilities that mediate self-tolerance, 
prevent autoimmune diseases and limit excessive immune responses. Tregs are 
a small population of CD4+ Helper T cells classically distinguished by the 
constitutive expression of CD25 and FOXP3 markers (Lee, 2017). CD25, the α-
chain of IL-2 receptor, was used in the mid 90’s to identify a small subset of mouse 
CD4+ Helper T cells responsible for maintaining self-tolerance (Sakaguchi et al., 
1995). Later it became clear that this population characterized as Tregs 
overexpresses CD25 and is able to suppress self-reactive T cells in mice (Suri-
Payer et al., 1998) as well as in humans (Baecher-Allan et al., 2001; Ng et al., 
2001). Although CD25 is constitutively expressed by Tregs, non-suppressive cells 
such as CD8+ and CD4+ T cells transiently upregulate CD25 during T cell activation 
and inflammation (Chaudhary and Elkord, 2016; Liu, Workman and Vignali, 2016). 
Thus, identification of Tregs exclusively by CD25 is inaccurate and inclusion of 
other markers might be valuable (Fontenot et al., 2005).  
In the early 2000’s the forkhead box P3 (Foxp3) gene was associated with the 
phenotype of scurfy mice. These mice develop fatal autoimmune disease due to 
spontaneous loss-of-function mutations in the Foxp3 gene (Brunkow et al., 2001). 
Similarly, humans with IPEX syndrome (Immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked) harbor deleterious mutations in the 
FOXP3 gene and develop strong autoimmune diseases (Bennett et al., 2001). 
Shortly after the description of FOXP3 gene, studies from Sakaguchi and 
Rudensky groups revealed that FOXP3 protein (also known as scurfin) is highly 
expressed by Tregs and helped to coin FOXP3 as a master regulator of Treg 
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function (Fontenot, Gavin and Rudensky, 2003; Hori, Nomura and Sakaguchi, 
2003). FOXP3 regulates the expression of genes responsible for mediating Treg 
suppressive features (Zheng et al., 2007; Frydrychowicz et al., 2017).  
Notwithstanding a variety of functions that sustain immune homeostasis, Tregs 
might also populate tumors promoting tolerance to tumor-associated antigens 
(TAAs) and suppressing anti-tumor immunity (Nishikawa and Sakaguchi, 2010). 
Tregs are routinely found in inflamed tumors that exhibit great amounts of CTLs 
and TH1 cells (Togashi, Shitara and Nishikawa, 2019). Due to their highly 
immunosuppressive features and infiltration in the TME, Tregs are considered a 
critical hurdle to favorable outcome of immunotherapies (Chao and Savage, 2018). 
Intratumoral Tregs may disrupt the mechanisms of immunosurveillance and 
support tumor development (Yamaguchi and Sakaguchi, 2006; Takeuchi and 
Nishikawa, 2016; Togashi, Shitara and Nishikawa, 2019). Depletion of tumor 
resident Tregs results in increased infiltration of tumor inhibitory cells (Li et al., 
2010) accompanied by effective anti-tumor immune response (Shimizu et al., 
1999).  
Tregs impair the immune response against tumors mediated by TH1 CD4+ T 
Helper cells (Casares et al., 2003), DCs (Chen et al., 2017), CTLs (Chen et al., 
2005) and NK cells (Pedroza-Pacheco, Madrigal and Saudemont, 2013). Tregs 
have four basic mechanisms of immunosuppression including inhibitory cytokines, 
IL-2 consumption, cytolysis and modulation of DCs functions (Vignali, Collison and 
Workman, 2008). A diagrammatic representation of the immunosuppressive 
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mechanisms of Tregs that limit the anti-tumor immunity in the TME is shown in 
Figure 3.1. 
Tregs disrupt immune response against tumor through secretion of 
immunosuppressive cytokines TGF-β and IL-10 (Yi et al., 2013). TGF-β impairs 
the development, proliferation, and function of anti-tumorigenic cells in the TME 
(Pickup, Novitskiy and Moses, 2013). Accordingly, TGF-β derived from Tregs 
mitigates anti-tumor immunity (Hilchey et al., 2007). There is a positive correlation 
between high levels of TGF-β and reduced survival in patients with melanoma 
(Tang et al., 2015). Similarly, IL-10 allows evasion of tumor cells from immune 
destruction in TME (Mannino et al., 2015) and high expression of IL-10 is 
associated with poor prognosis for melanoma patients (Dummer et al., 1995; 
Nemunaitis et al., 2001). A key mechanism of IL-10 immunosuppression is the 
impairment of antigen presentation (Sato et al., 2011). IL-10 secreted by Tregs 
hampers immune response against tumors in a contact-independent mechanism 
(Bergmann et al., 2007). IL-35 is another cytokine required for maximal Treg 
suppression action (Vignali, Collison and Workman, 2008). Tregs are the main 
source of IL-35 in the TME and this cytokine limits the generation of tumor-specific 
CTLs as well as promotes intratumoral T cell exhaustion. Furthermore, Treg-
specific depletion of IL-35 hampers tumor growth (Turnis et al., 2016).  
Although Tregs do not produce IL-2 (Papiernik et al., 1998), due to IL-2Rα 
(CD25) overexpression they constitutively uptake the IL-2 available in the 
microenvironment (Thornton and Shevach, 1998). Competition for IL-2 
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concurrently results in Tregs proliferation and inhibition of effector T cell growth 
since it depletes the IL-2 required for effector T cell propagation (de la Rosa et al., 
2004). Early in tumor development, when effector T cells are still producing IL-2, 
the upregulation of IL-2Rα in Tregs reduces the availability of this cytokine limiting 
T cell proliferation (Liu, Workman and Vignali, 2016).  
Secretion of granzyme and perforin leading to cytolysis of target cells is 
classically associated with activity of cytotoxic cells (i.e. CTLs and NK). After 
encountering its target, a cytotoxic cell releases granule containing perforin and 
granzymes. Perforin creates pores in the target cell allowing granzyme to access 
the cytosol and activate caspases (Lieberman, 2003). Unexpectedly, upon 
activation, Tregs were shown to express high levels of granzyme B (GZB) and 
exhibited cytotoxicity against different human cell lines (Grossman et al., 2004). 
GZB and perforin produced by intratumoral Tregs suppress the anti-tumor 
response of NKs and CTLs. It is estimated that 5-30% of tumor resident Tregs 
express GZB (Cao et al., 2007).  
DCs functions are controlled by Tregs and this regulatory mechanism indirectly 
affects the function of effector T cells given that functional DCs are required for 
activation of T cells (Vignali, Collison and Workman, 2008). Tregs constitutively 
express the inhibitory receptor CTLA-4 (Read, Malmström and Powrie, 2000). 
CD28 exhibited on the surface of naïve T cells competes with CTLA-4 for B7 
expressed by DCs. Notably, CTLA-4 has stronger affinity for B7. The interaction of 
CTLA-4 with B7 co-stimulatory molecule inactivates DCs and consequently 
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prevents the activation of effector T cells (Lee, 2017). Tregs employ CTLA-4 to 
hamper tumor immunity as CTLA-4-deficient Tregs exhibit reduced suppression 
which resulted in improved immune response against tumor (Wing et al., 2008). 
Tregs represent only 2-10% of CD4+ T cells in the peripheral blood of healthy 
patients. In contrast, it is estimated that Tregs account for 20-50% of CD4+ T cells 
present in the TME (Takeuchi and Nishikawa, 2016; Togashi, Shitara and 
Nishikawa, 2019). The prognostic value of Treg infiltrate for patients with cancer is 
still contentious and depends on tumor site (DeLeeuw et al., 2012). In many types 
of cancers heavy Treg infiltration is connected with reduced survival of patients 
(Nishikawa and Sakaguchi, 2010; Chaudhary and Elkord, 2016). Still, the absolute 
number of intratumoral Tregs is not always correlated with patients’ survival (Sato 
et al., 2005). It has been suggested that increased ratio between Tregs and 
effector lymphocytes is a more reliable prognostic indicator (Chaudhary and 
Elkord, 2016) since it demonstrates that Tregs are efficiently suppressing anti-
tumor immune responses (Takeuchi and Nishikawa, 2016). High incidence of 
intratumoral Tregs is associated with poor prognosis in patients with melanoma 
(Knol et al., 2011), glioblastoma (Sayour et al., 2015) and many carcinomas 
including lung (Tao et al., 2012), pancreatic (Tang et al., 2014) and ovarian cancer 
(Curiel et al., 2004). On the other hand, in patients with colon (Frey et al., 2010) 
and gastric tumors (Haas et al., 2009), whose tumorigenesis are associated with 
long term inflammation, the immunosuppression associated with Tregs provides a 
shielding effect against tumor formation. Thus, a high number of intratumoral Tregs 
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in these tumor types are linked to improved prognosis (Chaudhary and Elkord, 
2016; Frydrychowicz et al., 2017).  
Targeting of Tregs considerably improves tumor immunity and during the past 
few years immunotherapy strategies aiming to mitigate Tregs suppressive 
mechanisms have reached promising outcomes (Lee, 2017). Immunotherapy 
using monoclonal antibodies against CTLA-4 (ipilimumab) promotes activation of 
effector T cells (Maker, Attia and Rosenberg, 2005) resulting in improved outcome 
for patients with metastatic melanoma (Schadendorf et al., 2015). The mechanism 
of action of ipilimumab is still not completely understood. It is assumed that 
ipilimumab prevents Tregs from obstructing effector T cells activation mediated by 
DCs (Liu, Workman and Vignali, 2016; Lee, 2017). It has also been suggested that 
ipilimumab selectively depletes Tregs through an antibody-dependent cellular 
cytotoxic mechanism (Simpson et al., 2013).  
Chronic inflammation and long-term immunosuppression are uncontrolled 
immune events that impact tissue microenvironment and endorse tumor formation 
and development (Quail and Joyce, 2013; Palucka and Coussens, 2016). Treg-
mediated immunosuppression in the melanoma microenvironment is a relevant 
mechanism of escape from immune detection during the immunoediting process 
(Jacobs et al., 2012). Endothelins are considered pro-inflammatory cytokines 
given that they stimulate inflammatory response (Nett et al., 2006). Despite 
extensive studies that explored the immunoregulatory features of endothelins,  
how these cytokines negatively regulate immune response, particularly anti-tumor 
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immunity, is still poorly understood. Furthermore, the effect of endothelin on 
immunosuppressive cells such as Tregs has not been elucidated. The present 
study addressed the inhibitory effect of endothelin signaling during the immune 
response against melanoma.  
3.2. Results  
 Endothelin is required for immune escape of YUMMER1.7 cells 
Highly immunogenic YUMMER1.7 cells were intradermally injected in wild-type 
and K5-Edn3 mice to evaluate whether activation of endothelin signaling in the 
melanoma microenvironment is required for immune escape. YUMMER1.7 cells 
were originated from YUMM1.7 cells after rounds of UV radiation followed by clonal 
selection. YUMMER1.7 cells have a higher mutation load compared to YUMM1.7 
cells that elicited anti-tumor response. YUMMER1.7 cells exhibited tumor 
regression after injection in immunocompetent mice. YUMMER1.7 cells generated 
small tumors in wild-type mice 5 days after injections. These tumors began to 
shrink 8 days after injection and completely regressed 19 days post-injection 
(Figure 3.2). Initially, YUMMER1.7 tumors developed in K5-Edn3 mice had similar 
growth rate to those in wild-type mice. However, after a short period of relapse, 
tumors escaped regression and resumed growth at day 12. Tumor growth was 
maintained even after the complete regression observed in wild-type tumors 
(Figure 3.2). This finding suggests that the presence of endothelin in melanoma 
microenvironment may promote evasion from immune destruction.    
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 Endothelin increases the expression of Tregs-associated markers  
Real-time quantitative PCR was carried out to investigate whether 
overexpression of Edn3 in the melanoma microenvironment affects the expression 
of Treg-associated markers. qRT-PCR revealed that YUMM1.7-GFP melanoma 
tumors from K5-Edn3 mice had increased expression of Foxp3, Tgf-β and Il-10 
genes when compared to tumors from control mice (Figure 3.3).  
Next, I sought to confirm if the augmented expression of these genes was 
maintained at proteic level. The expression of FOXP3 protein in YUMM1.7-GFP 
tumors was examined using Western Blotting. The result supported the qRT-PCR 
data and showed that K5-Edn3 tumors exhibited remarkably higher expression of 
FOXP3 when compared to wild-type tumors. FOXP3 expression in experimental 
tumors was two times higher (p<0.05) than control tumors (Figure 3.4). TGF-β and 
IL-10 are two inhibitory cytokines that mediates the suppressive functions of Tregs. 
The expression of these immunosuppressive cytokines was evaluated using 
different approaches. The visual inspection of four sections per tumor from 
YUMM1.7-GFP tumors (n=4/group) did not detect TGF-β expression in wild-type 
tumors while TGF-β expression was observed in the microenvironment of K5-Edn3 
tumors (Figure 3.5). This result is in accordance with qRT-PCR data. Interestingly, 
TGF-β expression was mostly detected in extracellular space suggesting 
suppression by TGF-β occurs in a contact-independent manner. The production of 
IL-10 cytokine in the YUMM1.7-GFP tumors was quantified using IL-10 ELISPOT. 
In K5-Edn3 tumors there was a significantly increased number (p<0.01) of IL-10+ 
spots when compared with wild-type tumors (Figure 3.6). K5-Edn3 tumors had on 
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average 193 IL-10+ spots while wild-type tumors had an average number of 11 IL-
10+ spots. This result corroborated the observation that at the mRNA level IL-10 
expression is higher in K5-Edn3 tumors.  
Quantification of GZB expression was performed by immunofluorescence in 
YUMM1.7-GFP tumors. Experimental tumors showed approximately four times 
more GZB expression (p>0.01) when compared to control tumors (Figure 3.7). To 
confirm that GZB expression is restricted to Tregs, FOXP3 should have been co-
stained with GZB. Unfortunately, FOXP3 antibody did not work properly for 
immunofluorescence staining. Therefore, due to technical limitations it was not 
possible to rule out that other cell types in melanoma TME also express GZB.  
 Ednrb+ Tregs suppress cytotoxic cells 
To address whether the anti-tumor response in melanoma is counterbalanced 
by intratumoral Tregs expressing Ednrb, flow cytometric data was used to calculate 
the relative number of Ednrb+ Tregs to CTLs. This approach can demonstrate if 
Tregs are efficiently suppressing anti-tumor immune responses. K5-Edn3 tumors 
exhibited an Ednrb+ Tregs/CTL ratio three times higher (p<0.05) compared to wild-
type tumors (Figure 3.8). This finding indicates that activation of endothelin 
signaling in Tregs prevents expansion of CTLs.  
 Immune checkpoint and Ednrb inhibitor decreased melanoma growth 
To test whether the combination of immune checkpoint inhibitor with Ednrb 
blockage is a viable strategy to prevent melanoma growth, K5-Edn3 mice bearing 
YUMM1.7-GFP tumors were treated with CTLA-4 blocking antibody alone or in 
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combination with Ednrb inhibitor (BQ-788) for three weeks. Mice in the control 
group received treatment of DMSO along with isotype control and developed large 
tumors by the end of the treatment (average volume of 1,829 mm3) (Figure 3.9A). 
Tumors treated with anti-CTLA-4 exhibited a growth rate similar to the control 
group until day 13 of treatment. After that day, anti-CTLA-4 treatment significantly 
prevented tumor growth (p<0.05) (Figure 3.9A). Tumors treated with anti-CTLA-4 
had an average volume of 432.03 mm3 when treatment was concluded. Treatment 
exclusively with BQ-788 and in combination with anti-CTLA-4 remarkably reduced 
melanoma growth (p<0.0001) (Figure 3.9A). Indeed, some mice in these groups 
showed complete tumor regression. Tumors responded to BQ-788 earlier than 
anti-CTLA-4 although the volume of tumors from these groups were not statically 
different (p>0.05) (Figure 3.9A). The response to BQ-788 was so accentuated that 
no difference (p>0.05) was observed when tumors treated only with BQ-788 were 
compared to tumors treated with combination of BQ-788 and anti-CTLA-4 (Figure 
3.9B). The average tumor volume observed in BQ-788 group at the end of 
treatment was 8.8 mm3 and the combination group had an average volume of 
11.18 mm3. Altogether this data suggests that YUMM1.7-GFP tumors exposed to 
high levels of Edn3 are sensitive to immune checkpoint inhibitor as well as to Ednrb 
blockage, although the response to BQ-788 seems to be more noticeable.  
 Endothelin suppresses expression of inflammatory proteins in 
melanoma TME 
In order to identify novel factors impacted by endothelin overexpression in the 
melanoma microenvironment I performed an unbiased cytokine screen. 
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YUMM1.7-GFP tumors from wild-type and K5-Edn3 mice were harvested and 
changes in protein expression were analyzed by RayBiotech® Quantibody Mouse 
Cytokine Antibody Array. After normalization to internal controls, a group of 15 
cytokines was identified as differentially expressed (p<0.05) when wild-type and 
K5-Edn3 were compared (Figure 3.10A). K5-Edn3 tumors exhibited decreased 
levels of IL-28 (p<0.05) as well as the classical pro-inflammatory cytokine IL-17E 
(p<0.01) (Figure 3.10B). These results are in accordance with my previous findings 
and confirmed that endothelin signaling promotes immunosuppression in the 
melanoma microenvironment.  
3.3. Discussion 
The present study suggests that endothelin is an important component of the 
immunoediting process that takes places in melanoma development, particularly 
during the escape phase. YUMMER1.7 melanoma cells, which harbor a high 
mutational load, developed tumors in immunocompetent mice. These tumors were 
possibly detected by the tumor immunosurveillance system eliciting anti-tumor 
responses and tumor regression. A recent study demonstrated that YUMMER1.7 
tumor regression in immunocompetent mice is a process that relies on cells from 
the adaptive immune response (Wang et al., 2017). Tumors growing without 
abundant endothelin in the microenvironment regressed completely around 20 
days after injection. Conversely, when melanoma tumors grew in an End3-rich 
microenvironment they overcame immune destruction and evolved to tumors that 
did not regress. Therefore, the presence of endothelin in melanoma 
microenvironment facilitates the evasion from anti-tumor immunity.  
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Tregs suppress immune response against tumors and are considered central 
mediators for the escape from immune destruction (Takeuchi and Nishikawa, 
2016). Tregs infiltration is routinely found in patients with melanoma and these 
cells are considered functionally immunosuppressive (Vence et al., 2007). This 
study supports the notion that Tregs orchestrate immunosuppression in melanoma 
microenvironment. Enrichment of Tregs in melanoma tumors is generally 
associated with poor survival (Miracco et al., 2007; Mougiakakos et al., 2010; 
Gerber et al., 2014), although some studies did not find a correlation between Treg 
infiltration and melanoma outcome (Hillen et al., 2008; Ladányi et al., 2010). This 
discrepancy is probably due to the use of absolute number of Tregs rather than 
relative amount of Tregs to effector lymphocytes. Several preclinical studies have 
shown that a better outcome is achieved when melanoma tumors exhibited a ratio 
Treg/effector lymphocyte that favors effector cells (Nair et al., 2007; Cohen et al., 
2010; Shabaneh et al., 2018). Accordingly, less aggressive YUMM1.7-GFP tumors 
had a smaller ratio of Ednrb+ Tregs/CTLs when compared to aggressive tumors. 
This finding suggests that more CTLs are present in melanomas when there is no 
activation of endothelin signaling in Tregs. Thus, tumor immunity in melanoma 
microenvironment is hampered when Tregs are exposed to high levels of Edn3.  
Tregs are defined by the constitutive expression of CD25 and FOXP3 markers 
(Lee, 2017). Yet, CD25 is transiently expressed by CD8+ and CD4+ T cells (Liu, 
Workman and Vignali, 2016). It is thus possible that cells other than Tregs might 
have contributed to the increased numbers CD25+ cells observed in tumors 
growing in K5-Edn3 mice. FOXP3 is regarded as a reliable marker for murine 
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Tregs (Vignali, Collison and Workman, 2008). K5-Edn3 tumors showed 
augmented FOXP3 expression at mRNA and proteic levels relative to wild-type 
tumors confirming that there is an enrichment of Tregs when End3 is 
overexpressed in melanoma microenvironment. The mechanism adopted by 
endothelin to govern the accumulation of Tregs in K5-Edn3 tumors remains 
unclear. It is possible that endothelin impacted Tregs recruitment, proliferation, or 
conversion of conventional T cells into Tregs (Lee, 2017). The main mechanism 
responsible for Treg accumulation in tumors relies on chemokines system (Wang, 
Lee and Kim, 2012; Plitas et al., 2016). Given that the chemical structure of mature 
endothelin is very similar to that of other chemokines (Grimshaw, Wilson and 
Balkwill, 2002) it is tempting to claim that endothelin regulates the chemotactic 
trafficking of Tregs to melanoma microenvironment.  
Tumor intrinsic factors such as driver mutations might tolerate antitumor 
immunity in addition to promoting tumor formation (Togashi, Shitara and 
Nishikawa, 2019). A recent study demonstrated that early during tumorigenesis 
BRAFV600E is responsible for recruitment of Tregs to melanoma microenvironment 
and impaired tumor surveillance (Shabaneh et al., 2018). Importantly, Tregs are 
required for immune escape of BRAFV600E mutated YUMMER1.7 melanoma cells 
(Wang et al., 2017). The current study validates these previous findings. 
YUMM1.7-GFP melanoma cells, which harbor BRAFV600E mutation, developed 
tumors that express Treg marker FOXP3 in both wild-type and K5-Edn3 mice. 
Nevertheless, in K5-End3 tumors FOXP3 expression was augmented. This 
suggests that in an endothelin-rich microenvironment Tregs suppressive functions 
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are amplified. FOXP3 is considered the master regulator of Treg function (Togashi, 
Shitara and Nishikawa, 2019). Indeed, this transcription factor regulates the 
expression of genes that mediate the immunosuppressive features of Tregs 
including surface proteins CD25 and CTLA-4 and effector molecules IL-10 and 
GZB (Zheng et al., 2007). Genome-wide methylation comparison between human 
Treg and naïve T cell revealed 127 regions differentially methylated (RDM). 
Interestingly, EDNRB gene is among these RDMs in Tregs. EDNRB gene is 
hypomethylated and is considered a putative binding site of FOXP3. This finding 
implicates that EDNRB expression in Tregs is under the control of transcription 
factor FOXP3 (Zhang et al., 2013).     
Levels of immunosuppressive cytokines TGF-β and IL-10 were elevated in K5-
Edn3 tumors at both mRNA and proteic level indicating that endothelin stimulates 
the secretion of immunosuppressive cytokines in melanoma microenvironment. 
Since K5-Edn3 tumors exhibited enrichment of Tregs it is possible that these 
suppressive cells accounted for the augmented level of TGF-β and IL-10 in an 
endothelin-rich microenvironment. There is limited information regarding the 
association between endothelins and immunosuppressive cytokines IL-10 and 
TGF-β. It has been demonstrated that in mouse aorta and mesenteric artery IL-10 
antagonizes the vascular responses to Edn1 (Giachini et al., 2009). Consequently, 
in the context of vascular stimulation endothelin and IL-10 have conflicting effects. 
This is in contrast with the observed functions of endothelin and IL-10 in K5-Edn3 
tumors. Consistent with the present study, macrophages treated with endothelin 
exhibited increased expression of IL-10 and TGF-β (Soldano et al., 2016). 
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Furthermore, TGF-β and Edn1 displayed synergistic effects during vascular 
remodeling (Lambers et al., 2013).     
Tregs also employ contact-dependent mechanism to suppress effector cells, 
including production of GZB. It has already been demonstrated that production of 
GZB by intratumoral Tregs suppresses the anti-tumor response of NKs and CTLs 
(Cao et al., 2007). Single-cell RNA sequencing showed that Tregs isolated from 
melanoma tumors express GZB (Tirosh et al., 2016). GZB expression was 
accentuated in K5-Edn3 tumors. Given the increased ratio Ednrb+ Tregs/CTLs in 
K5-Edn3 tumors it is possible that the activation of endothelin signaling in Tregs is 
responsible for Treg-mediated cytolysis of CTLs. However, it is important to note 
that other cell types such as CTLs and NKs also express GZB (Lieberman, 2003). 
The data presented in this study is not sufficient to claim that in YUMM1.7-GFP 
tumors GZB expression is restricted to Tregs. Given that K5-Edn3 tumors exhibited 
a higher number of Tregs it is reasonable to propose that Tregs influenced the 
augmented GZB expression in K5-Edn3 tumors. 
Altogether these data suggest that when YUMM1.7-GFP tumors are exposed 
to a microenvironment rich in Edn3, the expression of markers associated with 
Treg function is augmented. Interestingly, markers of both contact-independent 
and contact-dependent mechanisms of Treg suppression were enhanced in K5-
Edn3 tumors. These findings implicate that endothelin signaling is required for 
immunosuppressive features of Tregs. Unexpectedly, endothelin which is 
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generally considered a pro-inflammatory cytokine seems to play an 
immunosuppressive role in the microenvironment of YUMM1.7-GFP melanoma. 
Therapeutic approaches aiming to block Treg functions have produced clinical 
success in melanoma. Immunotherapy using monoclonal antibodies against 
CTLA-4 (ipilimumab) results in improved outcome for patients with metastatic 
melanoma (Schadendorf et al., 2015). Blockage of Ednrb efficiently reduced 
melanoma growth in vitro and in vivo (Lahav, Heffner and Patterson, 1999). The 
present study investigated for the first time if the combination of Ednrb inhibitor 
(BQ-788) with immunotherapy using CTLA-4 blocking antibody is a therapeutic 
strategy that abrogate melanoma growth more effectively. YUMM1.7-GFP tumors 
exposed to a microenvironment rich in Edn3 responded to immune checkpoint 
inhibitor. YUMM1.7-GFP tumors exhibited a delayed response to anti-CTLA-4, 
which has been previously reported in patients with melanoma (Saenger and 
Wolchok, 2008). The mechanisms of action of CTLA-4 blocking antibody was not 
explored in detail in the K5-Edn3 mouse model. However, based on the elevated 
number of Tregs when YUMM1.7-GFP tumors are exposed to high levels of Edn3 
is possible to argue that anti-CTLA-4 prevented the T cell activation mediated by 
Tregs or even promoted Treg depletion (Togashi, Shitara and Nishikawa, 2019).   
Several in vitro and preclinical studies have demonstrated the anti-cancer effect 
of Ednrb blockage in melanoma (Lahav, Heffner and Patterson, 1999; Rosanò et 
al., 2004; Smith et al., 2017). The anti-tumor effect of Ednrb inhibition was more 
pronounced than immune checkpoint inhibitor in YUMM1.7-GFP tumors. Along 
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these lines, the potent effect of BQ-788 against melanoma has already been 
shown to be stronger than other therapeutic approaches such BRAF inhibition 
(Smith et al., 2017). Combination of anti-CTLA-4 with BQ-788 produced the same 
anti-tumoral effect that BQ-788 alone suggesting that Ednrb blockage is sufficient 
to prevent melanoma growth. The anti-tumor activity of anti-CTLA-4 was probably 
restricted to Tregs. Conversely, the striking anti-melanoma effect of BQ-788 might 
have been the consequence of Ednrb signaling blockage in Tregs as well as other 
cells in the TME. A recent study demonstrated that intratumoral administration of 
BQ-788 in melanoma patients reduced tumor growth and enhanced immune cell 
infiltration (Wouters et al., 2015). These data along with the present study support 
the idea that Ednrb blockage might effectively be employed as a therapeutic 
strategy for melanoma patients that express high levels of components of 
endothelin signaling.  
The present study indicates that endothelin presence in melanoma 
microenvironment enables the formation of an immunosuppressive milieu 
facilitating escape from tumor immunity. Tumors growing in abundance of 
endothelin exhibited remarkable reduction on the expression of chemokines and 
pro-inflammatory cytokines. Surprisingly, in K5-Edn3 tumors there was a 
significant reduction in the expression of chemokines CXCL11, CXCL2, CXCL12, 
CCL12 and CCL9. Chemokines regulate the recruitment of different populations of 
immune cells to TME (Nagarsheth, Wicha and Zou, 2017). Since immune cell 
populations (other than Tregs) did not differ when wild-type and K5-Edn3 tumors 
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were compared, it is possible that the presence of endothelin did not influence the 
overall trafficking of immune cells to melanoma microenvironment.  
IL-17 is a pro-inflammatory cytokine required for anti-tumor features of TH17 
cells during tumor immunosurveillance (Grivennikov, Greten and Karin, 2010). 
TH17 is an effector cell of tumor immunity and its presence in TME is associated 
with diminished numbers of Treg and increased amounts of CTLs and NK cells 
(Zou and Restifo, 2010). Reduction in the levels of IL-17F in K5-Edn3 tumors 
indicated that endothelin impaired tumor immunity in the YUMM1.7-GFP 
melanoma tumors. It has been shown that activation of EdnrA, but not Ednrb, 
stimulates the production of IL-17 in TH17 cells (Tanaka et al., 2014). Based on the 
observation that in presence of Edn3 there is downregulation of IL-17 it is plausible 
to argue that endothelin receptors might play ambiguous roles in TH17 cells as they 
do in DCs (Guruli et al., 2004). IL-28 is another cytokine that elicits anti-tumor 
response (Numasaki et al., 2007). Downregulation of IL-28 cytokine in K5-Edn3 
tumors was of particular interest given that the association between this cytokine 
and endothelin has not been previously described. The reduced levels of IL-28 in 
K5-Edn3 tumors corroborated the observation that endothelin weakened tumor 
immunity.  
During the last few years, a growing body of data have challenged the paradigm 
that endothelin exclusively stimulates inflammatory response. Expression of Ednrb 
on DCs decrease their maturation and survival suggesting that Ednrb negatively 
regulates immune response (Guruli et al., 2004). Endothelin promotes 
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macrophage polarization towards M2 phenotype, which are distinguished by their 
anti-inflammatory features. Indeed, Edn1 treatment stimulates macrophages to 
secrete immunosuppressive cytokines IL-10 and TGF-β (Soldano et al., 2016). 
EDNRB expression on endothelial cells impairs the homing of anti-tumor immune 
cells to TME (Aubert and Juillerat-Jeanneret, 2016). EDNRB decreases the 
expression of adhesion molecule ICAM-1 resulting in reduced recruitment of CTLs 
to ovarian cancer microenvironment. The negative impact of endothelin on 
lymphocyte homing is sustained even in presence of pro-inflammatory cytokine 
TNF-α. Hence, EDNRB activation in intratumoral endothelial cells creates an 
endothelial barrier that nourishes immune-privileged microenvironment. 
Importantly, EDNRB blockage increased the expression of adhesion molecules 
ICAM-1 in the vasculature followed by augmented homing of CTLs to TME 
(Buckanovich et al., 2008). Overexpression of EDNRB in endothelial cells from 
aggressive glioblastomas is associated with less CTL infiltrate and more Tregs 
present in TME. This finding implicates that high expression of EDNRB in TME 
impairs recruitment of tumor inhibitory immune cells while contributes to evasion 
of immune detection (Nakashima et al., 2016). These data together with the 
present study advocates for an immunosuppressive role of endothelin in TME 
resulting in escape from tumor immunity.   
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3.4. Methods  
 Tumor cell injection 
A total of 1,000,000 YUMMER1.7 melanoma cells (Wang et al., 2017) were 
intradermally injected in the shaved flank of K5-Edn3 or wild-type mice as 
described in 2.4.3. YUMMER1.7 cells were a gift from Dr. Marcus Bosenberg (Yale 
University). The study was approved by the Institutional Animal Care and Use 
Committee (IACUC) at Florida International University protocol number 16-018. 
 In vivo experiments 
K5-Edn3 mice were intradermally injected with 100,000 YUMM1.7-GFP as 
described in 2.4.3. When tumors became palpable (7 days after injection) mice 
were randomized into 4 groups (n=3) to receive the treatments three times per 
week for three weeks. Mice in the control group received intraperitoneal injection 
of DMSO and isotype control Syrian Hamster IgG2 (Bio X Cell, BP0087). Mice in 
the Ednrb inhibitor group were intraperitoneally treated with 10 mg/kg of BQ-788 
(ApexBio, BP3278). Mice in the immunotherapy group were treated with 10 mg/kg 
of anti-CTLA-4 (Bio X Cell, BP0131) clone 9H10 via intraperitoneal. Mice in the 
combination group were simultaneous treated with BQ-788 and anti-CTLA-4. 
Tumor volume was calculated as described in 2.4.3 and statistical analysis was 
carried out with One-Way ANOVA and considered to be significantly different at 
p<0.05.    
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 Real-time Quantitative PCR (qRT-PCR) 
Total RNA from YUMM1.7-GFP tumors was extracted using Direct-Zol® RNA 
MiniPrep Plus Kit (Zymo Research, R2070). Complementary DNA (cDNA) 
synthesis was performed using RevertAid First Strand cDNA Synthesis Kit 
(Thermo Scientific, K1622). Real-time quantitative PCR (qRT-PCR) was 
conducted using Thermo Scientific Maxima SYBR Green Master Mix (Thermo 
Scientific, K0221). Each sample was analyzed in triplicates and the relative mRNA 
expression levels of FOXP3, TGF-β and IL-10 were normalized to those of 
GAPDH. Primers sequences were as follows: FOXP3: forward 
CCCAGGAAAGACAGCAACCTT, reverse TTCTCACAACCAGGCCACTTG; 
TGF-β: forward CCTGCAAGACCATCGACATG, reverse 
TGTTGTACAAAGCGAGCACC; IL-10: forward ATAACTGCACCCACTTCCCA, 
reverse GGGCATCACTTCTACCAGGT; GAPDH: forward 
TGCAGTGGCAAAGTGGAGAT, reverse TTTGCCGTGAGTGGAGTCATA.  
 Western Blotting 
Harvested YUMM1.7-GFP tumors were lysed using RIPA lysis buffer. Tissue 
lysates were centrifuged at 16,000rpm at 4°C for 15min. The supernatant was 
collected and denaturated using 4x NuPAGE LDS Sample Buffer with 5% β-
mercaptoethanol. Pre-cast 4-12% SDS-PAGE gels were used to analyze the 
protein samples which were subsequently transferred to PVDF membrane. The 
membranes were incubated with FOXP3 (1:1,000, Proteintech, 22228-1-AP) and 
β-actin (1:4,000, Proteintech, 20536-1-AP) antibodies followed by HRP conjugated 
secondary antibody (1:5,000, Cell Signaling Technology, 7074) incubation. Finally, 
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the labeled proteins were visualized using chemiluminescence kit (Thermo 
Scientific, 34577). Bands intensity were quantified using ImageJ software. 
Statistical analysis was carried out with Student T-Test and considered to be 
significantly different at p< 0.05.   
 Immunofluorescence Analysis 
TGF-β (1:100, Abcam, ab92486) and GZB (1:100, Abcam, ab53097) primary 
antibodies were used for immunofluorescence staining. The procedure was 
performed as described in 2.4.5. GZB immunofluorescence staining was quantified 
in terms of mean fluorescence intensity using ImageJ software. Twenty random 
fields of four sections per tumor (n=4/group) were analyzed. Statistical analysis 
was carried out with Student T-Test and considered to be significantly different at 
p<0.05. 
 IL-10 ELISPOT 
MultiScreen® 96-well plates (Millipore, MAIPS4510) were coated with mouse 
IL-10 ELISPOT detection antibody (BD Biosciences, 51-9002752) and incubated 
overnight at 4°C, washed three times with PBS and blocked with DMEM 10% FBS 
for 2h at 37°C. Single-cells suspension from harvest YUMM1.7-GFP tumors were 
prepared as described in 2.4.4. A total of 1,000,000 cells derived from tumor 
dissociation were seeded in triplicates and incubated for 24h. After incubation wells 
were washed three times with wash buffer (0.05% Tween-20 in PBS) and 
incubated for 2h at room temperature with biotinylated mouse IL-10 ELISPOT 
capture antibody (BD Biosciences, 51-9002772). Following incubation, wells were 
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washed three times with wash buffer and incubated with avidin-HPR (Invitrogen, 
18-4100-51) for 2h at room temperature. Spots were developed after incubation 
with AEC Substrate Solution for 3min at room temperature. IL-10+ spots were 
counted using CTL Immunospot S6 ELISPOT reader. Statistical analysis was 
carried out with Student T-Test and considered to be significantly different at 
p<0.05.     
 Cytokine array 
Protein homogenates were prepared as described in 3.4.4. RayBiotech® 
Quantibody Mouse Cytokine Antibody Array (QAM-CAA-4000; RayBiotech) was 
conducted by RayBiotech. This assay simultaneously detects and quantifies 200 
cytokines and consisted of a multiplexed sandwich ELISA-based quantitative array 
platform. The fluorescence intensity levels were normalized to internal positive 
controls present in each array. Statistical analysis was carried out with Student T-
Test and proteins were considered differentially expressed when p<0.05.  
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3.5. Figures 
 
 
Figure 3.1 Immunosuppressive mechanisms of Treg in TME 
Tregs have many immunosuppressive mechanisms that limit anti-tumor immunity in 
TME. Tregs produce immunosuppressive cytokines TGF-β, IL-10 and IL-35 and uptake 
available IL-2 through overexpression of CD25. Tregs also express granzyme B (GZB) 
to directly kill CTLs and NK cells and prevent the co-stimulatory signaling in DCs through 
expression of immune checkpoint CTLA-4.   
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Figure 3.2 Endothelin is required for immune escape of YUMMER1.7 melanoma 
cells 
Tumor volume of mice (n=5) that received intradermal injections of YUMMER1.7 
melanoma cells. **p<0.01 
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Figure 3.3 Endothelin increases the expression of Tregs-associated markers in 
the YUMM1.7-GFP melanoma tumors 
qRT-PCR analysis of Foxp3, Tgf-β and Il-10 mRNA levels in wild-type and K5-Edn3 
tumors. Fold change was calculated as the relative mRNA amount of target gene in 
wild-type and K5-Edn3 tumors normalized to GAPDH. Shown is one of the three 
experiments performed. 
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Figure 3.4 Endothelin increases FOXP3 expression in YUMM1.7-GFP melanoma 
tumors 
A. Western blot analysis of FOXP3 and β-actin expression in intradermally injected 
YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice. B. Densitometric analysis of 
FOXP3 expression relative to β-actin expression (n=3/group). *p<0.05. 
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Figure 3.5 Endothelin increases TGF-β expression in YUMM1.7-GFP melanoma 
tumors 
Immunofluorescence staining of intradermally injected YUMM1.7-GFP tumors of wild-
type (A) and K5-Edn3 (B) mice for TGF-β. TGF-β expression was observed only in K5-
Edn3 tumors. 
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Figure 3.6 Endothelin increases IL-10 expression in YUMM1.7-GFP melanoma 
tumors 
A. Representative wells of IL-10 ELISPOT of intradermal YUMM1.7-GFP tumors of wild-
type and K5-Edn3 mice. B.  Quantification of IL-10+ cells. **p<0.01. Shown is one of the 
two experiments performed. 
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Figure 3.7 Endothelin increases granzyme B (GZB) expression in YUMM1.7-GFP 
melanoma tumors 
A. Immunofluorescence staining in YUMM1.7-GFP intradermal tumors of wild-type (left) 
and K5-Edn3 (center) mice for Granzyme. B. Mean fluorescence intensity analysis of 
20 random fields per tumor (n=4/group). **p<0.01. 
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Figure 3.8 Endothelin increases the number of Ednrb+ Tregs relative to cytotoxic 
cells in YUMM1.7-GFP melanoma tumors 
Flow cytometric quantification of Treg Ednrb+ relative to CTLs cells from intradermal 
YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice (n=3/group). *p<0.05. 
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Figure 3.9 Immune checkpoint and Ednrb inhibitor decreased melanoma growth 
K5-Edn3 mice bearing YUMM1.7-GFP tumors were treated with BQ-788 (10 mg/Kg) 
alone, anti-CTLA-4 (10 mg/Kg) alone or in combination three times a week for three 
weeks. A. Tumor volume of K5-Edn3 mice that received drug treatments (n=3). B. 
Representative tumor of each group after resection. *p<0.05, ***p<0.0001  
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Figure 3.10 Endothelin suppress the expression of inflammatory proteins in 
YUMM1.7-GFP melanoma tumors 
Changes in protein expression of the YUMM1.7-GFP tumors of wild-type and K5-Edn3 
were analyzed by RayBiotech Quantibody® Mouse Cytokine Array. The fluorescence 
intensity levels were normalized to internal positive controls present in each array. 
Normalized fluorescence intensity for 15 differentially expressed proteins (p<0.05) are 
represented in the heat map (A) and as the mean +/-S.E.M. (B) (n=3/group).  *p<0.05, 
**p<0.01. 
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4.1. Conclusions and Implications 
Melanoma is the deadliest type of skin cancer accounting for 75% of all deaths 
related to cutaneous tumors (Schadendorf et al., 2015). The high mortality rate 
associated with melanoma is due to its remarkable metastatic potential (Damsky, 
Theodosakis and Bosenberg, 2014). Many cytokines are associated with 
melanoma progression, among them are the endothelins. Endothelins are 
cytokines ubiquitously expressed in the microenvironment of several tumors 
(Nelson et al., 2003). In carcinomas and glioblastoma the components of 
endothelin signaling are expressed by different cell types within TME (Aubert and 
Juillerat-Jeanneret, 2016). In melanoma is not clear whether stromal cells respond 
to the endothelin present in the microenvironment. 
The present study corroborated previous findings (Demunter et al., 2001; Tang 
et al., 2008) demonstrating that Edn3/Ednrb signaling activation in melanoma 
increases tumor aggressiveness. In this study I showed that activation of 
endothelin signaling mediated aggressiveness of a broad range of melanomas, 
including BRAFV600E and BRAF wild-type melanomas. Few melanoma cells 
expressed Ednrb in the YUMM1.7-GFP melanoma microenvironment suggesting 
an environmental role for endothelin signaling in melanoma microenvironment. 
The present study showed for the first time that Ednrb is expressed in several cell 
populations inside melanoma microenvironment. The clinical relevance of this 
finding was validated using publicly available RNA-seq data from melanoma 
patients (Tirosh et al., 2016). To a certain extent, Ednrb was expressed in both 
pro- and anti-tumorigenic cells indicating that endothelin activation might have 
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multiple effects in melanoma microenvironment. Since K5-Edn3 tumors exhibited 
a more aggressive phenotype it is possible that in Edn3-rich microenvironment the 
net result benefited pro-tumorigenic cells. To date, no other study has shown 
Ednrb expression in intratumoral Tregs. Treg was the only population that was 
numerically different when K5-Edn3 tumors were compared to wild-type tumors. 
This data suggests that when Edn3 is present in melanoma microenvironment 
there is an enrichment of intratumoral Tregs. Tumor-infiltrating Tregs suppress 
anti-tumor immunity (Nishikawa and Sakaguchi, 2010). Therefore, it is reasonable 
to claim that in abundance of Edn3 Tregs create an immunosuppressive 
environment in melanoma tumors granting escape from immunosurveillance.  
Melanoma is recognized as one of the most immunogenic types of tumors 
(Passarelli et al., 2017). Melanoma also develops an immunosuppressive 
microenvironment resulting in evasion from immune detection and ultimately 
metastasis formation (Umansky and Sevko, 2012). Endothelins are commonly 
considered pro-inflammatory cytokines given their stimulatory roles during 
inflammatory response (Nett et al., 2006). Over the past years, mounting data have 
challenged the paradigm that endothelin solely stimulates inflammatory response. 
The present study supports the notion that endothelin promotes the formation of 
an immunosuppressive milieu in melanoma facilitating escape from tumor 
immunity. Endothelin was required for immune escape of highly immunogenic 
melanoma cells YUMMER1.7. Tregs orchestrated immunosuppression in 
YUMM1.7-GFP melanoma tumors. FOXP3 is considered the master regulator of 
Tregs suppressive functions (Fontenot, Gavin and Rudensky, 2003; Hori, Nomura 
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and Sakaguchi, 2003). FOXP3 was remarkably upregulated in K5-Edn3 tumors 
confirming that Edn3 overexpression in melanoma microenvironment is associated 
with Treg enrichment. Tregs disrupt immune response against tumor through the 
secretion of immunosuppressive cytokines TGF-β and IL-10 (Yi et al., 2013). 
Accordingly, K5-Edn3 tumors exhibited high levels of TGF-β and IL-10. This 
observation suggested that in presence of Edn3, the immunosuppressive features 
of Tregs are enhanced. Indeed, activation of endothelin signaling in Tregs 
prevented the expansion of CTLs possibly via GZB-mediated cytolysis. These data 
indicated that the response of Tregs to endothelin impaired immune response 
against melanoma. Unexpectedly, expression of chemokines and inflammatory 
cytokines were downregulated in K5-Edn3 tumors. Cytokines that elicit anti-tumor 
immunity, namely IL-17E and IL-28 (Numasaki et al., 2007; Zou and Restifo, 2010), 
exhibited reduced levels in K5-Edn3 tumors. This result endorsed the idea that 
endothelin mitigated tumor immunity in YUMM1.7-GFP melanoma tumors. 
Importantly, this is the first report to associate overexpression of endothelin with 
reduction of IL-28 production. YUMM1.7-GFP tumors exposed to high levels of 
Edn3 were sensitive to immune checkpoint inhibitor (anti-CTLA-4) as well as to 
Ednrb blockage (BQ-788), although the response to BQ-788 was more 
pronounced. 
Metastatic melanoma has a very poor prognosis with the 1-year overall survival 
rate around 25% (Korn et al., 2008). Although YUMM1.7-GFP tumors responded 
to high levels of Edn3 by growing larger, few metastatic lesions were observed, 
and only in K5-Edn3 mice. YUMM1.7 cells mirror the genetic alterations commonly 
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found in human melanomas, namely BRafV600E/+;Pten-/-; Cdkn2a-/- mutations, but 
were shown to have limited metastatic features (Meeth et al., 2016). Therefore, the 
findings from the present study should be viewed with caution regarding melanoma 
metastasis.  
The anti-metastatic potential of immune checkpoint and Ednrb inhibitors was 
not assessed in the current study. Still, YUMM1.7-GFP tumors exposed to high 
levels of Edn3 were sensitive to immune checkpoint inhibitor and Ednrb blockage 
as both treatments significantly decreased tumor growth. Increased tumor volume 
is correlated with elevated likelihood of melanoma dissemination to distant organs 
(Walton et al., 2015). Thus, it is plausible that, in the context of Edn3 
overexpression, immune checkpoint inhibitor as well as Ednrb blockage may have 
prevented melanoma metastasis formation.      
Altogether the data in the present study advocate for an environmental role of 
Edn3/Ednrb signaling in melanoma. Endothelin mediates immunosuppression in 
melanoma microenvironment resulting in escape from tumor immunity. These 
findings are summarized in Figure 4.1. The present study endorses the framework 
that endothelin signaling may have multiple effects in the melanoma 
microenvironment given that melanoma cells and different populations of stromal 
cells expressed Ednrb in the YUMM1.7-GFP tumors. Melanoma cells may be 
directly affected by an Edn3-rich microenvironment. It has already been shown that 
melanoma cells express EDNRB (Asundi et al., 2011; Bagnato et al., 2004b; 
Lahav, Heffner, & Patterson, 1999; Yohn et al., 1994). Activation of EDNRB on 
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melanoma cells triggers many cellular events relevant for tumor progression such 
as proliferation, migration, and invasion of melanoma cells (Bagnato et al., 2004a). 
Endothelins are also secreted by melanoma cells (Chiriboga et al., 2016; Tang et 
al., 2008). In the context of Edn3 overexpression, it is possible that the autocrine 
activation of Ednrb in melanoma cells enhanced the abovementioned cellular 
events.   
Abundance of Edn3 in the melanoma microenvironment might also have 
indirectly favored melanoma cells. Activation of endothelin signaling in fibroblasts 
induces secretion of ECM components and metalloproteinases (Knowles et al., 
2012), which might have created a permissive stroma for melanoma cell growth 
and invasion. Endothelin signaling controls angiogenic events in endothelial cells 
(Salani, Taraboletti, et al., 2000). New blood vessels increase nutrient supply to 
tumor cells as wells as create new routes for metastatic cell dispersion (Smith and 
Kang, 2013). YUMM1.7-GFP melanomas from both wild-type and K5-Edn3 mice 
exhibited anti- and pro-tumorigenic immune cells expressing Ednrb, which 
indicates potential opposite functions of endothelin signaling in the melanoma 
microenvironment. Given that K5-Edn3 tumors have a more aggressive 
phenotype, it is reasonable to suggest that an Edn3-rich microenvironment favors 
the effect of endothelin in pro-tumorigenic cells. The present study explored the 
suppressive role of Edn3 in the melanoma microenvironment. The context of 
impaired tumor immunity seems to benefit melanoma cells given that anti-tumor 
cells might become unable to recognize and kill cancer cells. 
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4.2. Future Directions  
The present study proposes that melanoma should be added to the roster of 
tumor types in which activation of endothelin signaling has a microenvironmental 
role. Ultra-violet light (UV) exposure is considered the major risk factor for 
melanoma (Lawrence et al., 2013). Interestingly, keratinocytes release endothelin 
upon UV light exposure (Imokawas, Yada and Miyagishi, 1992). In the K5-Edn3 
mouse model (Garcia et al., 2008) overexpression of Edn3 is restricted to 
keratinocytes. Thus, K5-Edn3 mice used in this study constitute a suitable system 
to explore the microenvironmental role of endothelin in melanoma. A different 
approach to validate the observations made using the K5-Edn3 mouse model 
would be the injection of melanoma cells in mice that lack expression of Ednrb. 
The piebald lethal (Ednrbsl »sl) mouse would be appropriate for further studies since 
it harbors spontaneous deletion in the Ednrb gene (Hosoda et al., 1994). Injection 
of YUMM1.7-GFP melanoma cells in piebald lethal mice would corroborate the 
microenvironmental role Edn3/Ednrb signaling in melanoma microenvironment. A 
similar strategy was employed to describe the stromal functions of Ednrb in breast 
cancer. Injection of breast cancer cells overexpressing Ednra generated tumors 
with diminished growth and metastatic potential in Ednrb deficient rat. Absence of 
stromal Ednrb impaired immune cells infiltration and cytokine production resulting 
in reduced tumor aggressiveness. Lack of Ednrb in TME decreased the 
recruitment of TAMs and the amount of pro-inflammatory cytokine TNF-α (Binder 
et al., 2009). 
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 The present study suggested that endothelin promotes evasion from tumor 
immunity in YUMMER1.7 melanomas. It has been demonstrated that Tregs 
prevents the regression of YUMMER1.7 tumors (Wang et al., 2017). It was not 
clear whether activation of Ednrb in Tregs mediated the impaired 
immunosurveillance in YUMMER1.7 tumors from K5-Edn3 mice. Flow cytometry 
experiments using Ednrb and CD25 antibodies should be performed in K5-Edn3 
tumors to test if activation of endothelin signaling in Tregs plays a role during 
YUMMER1.7 immune escape. Additionally, FOXP3 expression at mRNA and 
proteic level should be carried out in K5-Edn3 tumors to confirm that endothelin is 
required for Treg suppressive functions in YUMMER1.7 melanomas.        
The current data implicated that overexpression of Edn3 in melanoma 
microenvironment results in intratumoral Tregs enrichment. Still, the mechanism 
responsible for Tregs accumulation in K5-Edn3 tumors was not explored. It is 
possible that endothelin impacted Tregs proliferation, recruitment or conversion of 
conventional T cells into Tregs (Lee, 2017). In order to clarify the role of Ednrb 
activation in Tregs, suppressive cells should be isolated from tumors using Treg 
isolation kit (MACS Miltenyi Biotec, 130-091-041) and treated with Edn3. Treg 
proliferation can be addressed using CFSE dilution. The migratory effect of Tregs 
in response to endothelin could be assessed using Boyden chamber assay. To 
test if endothelin mediates the conversion of conventional T cells into Tregs 
isolated naïve CD4+ T cell should be cultivated in presence of Edn3. It is possible 
that isolation of intratumoral Tregs using Treg isolation kit yield a small number of 
cells. Alternatively, mouse spleen can be use as Treg source.  
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Production of GZB by intratumoral Tregs suppresses the anti-tumor response 
of NKs and CTLs (Cao et al., 2007). Nevertheless, GZB is also expressed by CTLs 
and NKs (Lieberman, 2003). Due to technical limitations, it was not possible to 
demonstrate that Tregs accounted for augmented expression of GZB in K5-Edn3 
tumors. In order to elucidate whether activation of endothelin signaling triggers 
GZB expression in Tregs, isolated Tregs should be cultured in presence of Edn3 
and GZB expression measured using qRT-PCR and Western Blotting.  
Preclinical studies have shown that Ednrb inhibition effectively reduced 
melanoma growth (Lahav, Heffner and Patterson, 1999; Spinella et al., 2007; 
Smith et al., 2017). The clinical relevance of EDNRB blockage is still elusive 
(Kefford et al., 2007; Wouters et al., 2015). This is probably due to the lack of 
previous screening for patients with high levels of EDNRB. Immunotherapy 
approaches using immune checkpoint inhibitors have reached exciting results in 
patients with melanoma. Yet, some patients do not respond to immunotherapies 
and new strategies are imperatively required (Binnewies et al., 2018). The data 
from the present study indicate that Ednrb blockage might improve the outcome of 
immunotherapies. Indeed, EDNRB blockage enhanced the results of 
immunotherapy in a preclinical study of ovarian cancer (Buckanovich et al., 2008). 
Additional studies using large cohorts should be carried out to validate the 
successful preliminary results of Ednrb inhibitor treatment in K5-Edn3 mice bearing 
YUMM1.7-GFP melanomas. Further, clinical trials aiming to block endothelin 
signaling might be performed in melanoma patients that express high levels of 
EDNRB and are under ipilimumab treatment.  
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4.3. Figure 
 
 
Figure 4.1 Microenvironmental role of Edn3/Ednrb signaling in melanoma 
Several cell types are present in the microenvironment of melanomas that express 
endogenous levels of Edn3. In these tumors there is reduced expression on 
immunosuppressive cytokines IL-10 and TGF-β as well as GZB. Chemokines and 
cytokines that elicit anti-tumor immunity are highly expressed in melanomas that exhibit 
endogenous levels of End3. Conversely, melanomas growing in Edn3-rich 
microenvironment exhibit enrichment of Ednrb+ Tregs. Endothelin promotes the 
formation of an immunosuppressive milieu characterized by augmented expression of 
immunosuppressive cytokines IL-10 and TGF-β as well as GZB and diminished levels 
of inflammatory cytokines and chemokines.         
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